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ABSTRACT

Title of the Study:

Health-related quality of life (HRQoL) as predictor of

medication adherence in patients infected with Human Immune-deficiency
Virus (HIV).

Summary: Quality of life (QoL) is a broad term which involves evaluation of

all aspects of life including, health, education, family life, housing, friendship,
marriage, standard of living, and work. Health is one of the domains that affect
our quality of life. The measurement of HRQoL is becoming an increasingly
common activity in healthcare systems around the world. Health-related quality
of life or biological outcome of treatment might predict adherence to HIV
medication. This research is aimed to study the effect of HRQoL on medication
adherence in patients infected with HIV. The original study was funded by NIH
and conducted by Dr. Cynthia Willey, at University of Rhode Island during the
years 1995-98. The purpose of the original project was to assess the stages of
changes for adherence with HIV-Related Medications. The sample consisted of
145 patients. The questionnaire was developed by AIDS Clinical Trial Group
(AACTG). Questionnaires were distributed to the patients in Rhode Island at
different sites affiliated with Brown University AIDS program. These sites
included:
1. The Miriam Hospital Immunology Center: This center serves majority of
the HIV positive women in Rhode Island.

2. Stanley Street Treatment and Resources: This center serves the Greater
Fall River Massachusetts area and provides care to indigent and
intravenous drug users.
3. Veteran Affairs Medical Center in Providence, Rl: This center treats
approximately 60 HIV positive men.

Methodology: The data was collected by administering a standardized self-

reported questionnaire to the subjects to assess the compliance to HIV drugs.
The questionnaire covered various aspects like, Demographic, Economic status,
Coping, Quality of life, Medication, etc. Four domains of health-related quality
of life were measured using 12 questions based on SF-36 included in the
questionnaire. Medication adherence was assessed as self-reported adherence
and also using Medication Adherence Scale. Univariate and bivariate tests were
run to check for confounding variables in the data set. Logistic regression was
used to determine any interaction between independent variables. The effect of
Quality of life domains on medication adherence were assessed by running
logistic regression model after controlling for potential confounding factors.

Results: The results of this study indicate that "vitality/fatigue" is significantly

associated with 95% self-reported adherence in patients taking protease
inhibitors. This study thus confirms that patients with better mental health are
more likely to adhere to their medication regimen. This is consistent with

previous findings by other researchers. No other meaningful association was
found between any other domain of QoL and medication adherence.
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INTRODUCTION

Acquired Immunodeficiency Syndrome (AIDS) is a significant healthcare, social, and
psychological problem facing the mankind. When AIDS emerged from the shadows
two decades ago, few people could predict how the epidemic would evolve, and fewer
still could describe the best ways of combating it. As we face the third decade of AIDS
epidemic, the impact of this disease is enormous. Human immunodeficiency virus is a
major public health problem in all parts of the world [1].

Worldwide, nearly 40 million people are living with human immunodeficiency virus
(HIV), which causes AIDS [2]. These include 19 .6 million males, 17 .6 million
females, and 2.7 million children (less than 15 years of age). Globally, AIDS is a
fourth leading cause of death [3]. In United States alone, approximately 1 million
people live with HIV infection [2]. HIV/AIDS has become one of the highest
expenditure infections in terms of cost of treatment and care provided, lost
productivity hours, and disability [ 1].

Mankind faces multiple challenges in fighting AIDS. Social stigma and discrimination
are the major obstacles to effective HIV/AIDS prevention and care. Fear of
discrimination may prevent people from seeking treatment for AIDS or from
acknowledging their HIV status.

Until quite recently, the disease was considered to carry an almost certain debilitating,
downward course leading to early death from opportunistic infections. Not long ago,
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zidovudine, a nucleoside analogue reverse transcriptase inhibitor, was the only drug
used to treat HIV. This drug interferes with the actions of specific HIV enzyme
involved in the replication of cycle of HIV.

But, the treatment of HIV virus has changed immensely. With advances in HIV
treatment regimens, HIV has become a treatable chronic illness that requires extensive
clinical management [4]. New potent drugs are prolonging the lives of thousands of
patients infected with HIV. There are now dozens of medications available to attack
different enzymes in HIV virus lifecycles. These drugs can be classified into three
categories depending on the enzymes they target in HIV lifecycle. These are:
1. Nucleoside reverse transcriptase inhibitors (NRTI's)
2. Non-nucleoside reverse transcriptase inhibitors. (NNRTI's)
3. Protease inhibitors (PI's)

Since the potential for mutation is very high with HIV, drugs are more effective when
used in combination. Convergent therapy uses drugs from same class to target same
enzyme, while divergent therapy used drugs from different class to target different
enzymes. The combination of both convergent and divergent therapy is called highly
active anti-retroviral therapy (HAART). The first of protease inhibitors were
introduced in 1995. Since the late 1997, when HAART was first introduced, the
combination of protease and reverse transcriptase inhibitors had proven effective in
driving HIV viral loads to very low or undetectable levels [5] . The most commonly
used combination includes one potent protease inhibitor and two NRTI' s. The impact
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of protease inhibitor based combination therapy has resulted in astonishing
improvements in survival [6]. The survival rates have increased with both longer
AIDS free survival and lower mortality [7] . This shift to the use of HAART for
treating HN has led to increasingly complex drug regimen [8] . Adherence has been
often called the "Achilles' heel" of highly active anti-retroviral therapy.

HAART is highly effective but the drugs have short half-lives and are highly selective,
leading to drug resistant strains if therapeutic levels are not maintained [9]. The longterm effectiveness of HAART is dependent upon achieving maximum and durable
suppression of HN plasma viral load [9, 10]. Even in successfully suppressed
patients, HN replication will rapidly rebound if HAART is discontinued. One of the
major challenges to good adherence to HAART has been complexity of regimens.
HIV medication regimens are complicated and require extensive time and effort from
the patient [ 11]. Many drugs need to be taken three times a day and the pill burden is
overwhelming i.e. 15 -20 pills daily. Some drugs need to be taken with food, some
without food and still others with dietary supplements. The complexity of HAART
regimen sometimes requires patients to change their eating and sleeping pattern. This
level of lifestyle change and accommodation may result in frustration and treatment
failure [12]. Non-adherence to HN treatment regimen is a primary cause of treatment
failure now. As a result of the pivotal role that adherence plays in the success of
HAART, a tremendous amount has been written emphasizing the importance of
adherence [5].
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Adherence, often used interchangeably with compliance, is "an act, action, or quality
of being consistent [13) with administration of prescribed medication". The term
adherence is preferred over compliance because it affirms patient's active participation
in choosing and maintaining a treatment regimen. The concept of adherence
additionally extends beyond medication management, to encompass a comprehensive
treatment plan.

Adherence simply means how accurately patients take their medications. One hundred
percent adherence to any medication regimen is not easy to achieve. One recent study
on adherence behavior in HN has shown that only 55-62% of patients are highly
adherent to their medication therapy [ 14]. Many factors have been shown to affect
patient's adherence.

Patient Factors and Health Beliefs: Demographic characteristics (like, age, gender,
race, etc.) have not been consistently found to be predictive of adherence [15, 16).
However, other factors like heavy alcohol use, drug abuse, and depression have been
found to be associated with adherence [17, 18). Various aspects of patients' beliefs
about the nature of their disease [11), perceived importance of medication used [12),
the health care system, and cultural factors affect medication adherence. Patients who
perceive that their disease is a "serious health problem" and believe that the prescribed
medications are necessary are more likely to adhere to prescribed medication regimens
[12). In general, increased knowledge about disease and purposes of therapies increase
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adherence [11]. However, concerns regarding safety of the medication on long term
and the medication side effects could decrease medication adherence.

Disease Factors: Investigations have found little relationship between type of illness
and level of adherence [ 16] . Patients experiencing extreme pain or who are
symptomatic are more likely to be adherent to their medications than patients who are
asymptomatic. Many patients interrupt or stop taking their medications when they are
asymptomatic.

Provider Factors: General satisfaction with medical care appears to have no bearing on
adherence. However, patient's dissatisfaction and unfulfilled expectations with the
treatment and the doctor results in low adherence rates [ 11, 19] . The quality of
interaction between doctor and patient can have major influence on health outcomes.
Provider-patient relationship, especially communication about chronic nature of
disease, the need for regular therapy, the role of medications, and discussion of side
effects improves patient adherence. Poor provider-patient communication is associated
with poor adherence. Affordability of medication, insurance coverage, and cost of
therapy is a barrier to achieving adherence.

Treatment complexities: Adherence is poorer in patients treated with more complex
regimens [11, 20]. It has also been shown that adherence normally decreases over time
and with greater number of pills that one is required to take [ 11]. One study measuring
compliance with inhaled medication in asthma showed that as medication dosing
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became more frequent, the adherence decreased from 71 % twice a day to 18% four
times a day [20]. Anticipatory fear of side effects and secondary effects of illness such
as nausea and dizziness can also reduce patient adherence.

Psychosocial Factors: Given the complexity of human behavior, multiple determinants
including patient characteristics may affect medication adherence. Behavior associated
with chaotic lifestyle, depression, alcohol and elicit drug use often reduce adherence
[11]. Patients with positive adaptive coping have been found to be more adherent to
their medications [21]. Other factors like, presence of stress, lack of motivation,
pessimism, and depression appears to result in non-adherence.

Patients having

sufficient levels of practical, emotional, and cognitive social support show higher level
of adherence [ 11, 22].

Adherence is an important factor to achieve best outcomes in RN disease
management. Although it is not known how adherent patients have to be to achieve
best results, but it is believed that more adherent the patients, the more likely he is to
have best results. Strict adherence to medication regimen yields high success. As more
emphasis is laid on maintaining low viral count in HIV-infected patients, adherence to
medication regiment has become an important issue [23]. Sub-optimal patient
adherence has been shown to be related to inadequate viral suppression [24], reduced
exposure to anti-retroviral drugs [25], the emergence to viral resistance [26], and RN
disease progression and mortality [26]. Since the virus has the ability to mutate rapidly
in absence of drug, taking anti-retroviral medication exactly as prescribed is the key

6

for success of therapy. HAART is very effective but drugs have short half-life and are
highly selective favoring drug-resistant strains if therapeutic levels are not maintained.
The rate of virologic failure sharply increases when less than 95 % of prescribed dose
of drug is actually taken [17] . In addition to taking adequate prescribed medication,
anti-retroviral and protease inhibitors need to be taken according to correct timeschedule, and for several drugs, dietary prescription. For most HIV-infected
individuals, the alternative to lifelong adherent therapy may be devastating
complication, often resulting in death.

Measuring Adherence:

One problem of measuring adherence is the lack of a standard measurement [ 15]. The
methods commonly used to measure adherence can be classified as direct or indirect
methods. Direct methods include pill count, biological assay, and electronic
monitoring method, whereas indirect methods use questionnaire, interviews, or diary
to estimate self reported adherence. All these methods have their respective
advantages and disadvantages as discussed below.

Self-Reported Medication Adherence: This is one of the simplest methods used to
measure adherence. Three main types of self reports have been used including
surveys, interviews and diaries. These involve asking patients how often they took (or
missed) their medications by use of variety of surveys. However, reports of nonadherence could be more reliable than reports of adherence. For example, the AIDS
Clinical Trials Groups survey asks patients how many medication doses they missed
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during previous day, 2 days or, 4 days. Despite the ease of administration, the self
reported adherence measure has several limitations. Investigations have revealed that
patients tend to overstate the actual adherence [27]. The patients want to present
socially acceptable responses. Even if the patients are truthful, there is no data to
prove how long the patients can remember what doses were missed several days ago
[27].

Pill Count: Many investigators use pill count as method of measuring adherence. The
pill count is generally done by study personnel like nurse, physician or, other health
care practitioner. Although pill count avoids the subjective evaluation of adherence
and has been demonstrate to correlate more highly with electronically measured
adherence [28], the proportion of doses measured by pill count often exceeds actual
number of doses taken. This method has several other limitations. Patients may forget
to bring the bottles to the pharmacy. Patents also 'pill dump' and dispose extra
medication doses to appear more adherent [29].

Biological Assays: Biological markers and tracer compounds indicate patient
compliance over an extended period [30]. Plasma levels of antiretroviral drugs provide
unequivocal evidence that the medication has been taken. To assess adherence using
this method, the time and dose of the medication must be noted. Also, repeated plasma
levels need to be withdrawn from the patient to improve the sensitivity of the test.
This measure also has some drawbacks. Firstly, plasma levels only measure adherence
to a dose prior to the visit or sample drawn [31]. Also, studies in many disease states
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have demonstrated, patients who are aware that they may have a clinical sample like
blood drawn to measure adherence will be more likely to adhere to the dose
immediately prior to the visit than to other doses [32] . Besides, the pharmacokinetics
of many drugs, especially protease inhibitors, varies significantly from person to
person [32].

Electronic Monitors: MEMS (Medication event monitoring system) and eDEM are
two commercially available monitors to measure adherence [15]. These devices are
fitted with special pill bottle caps equipped with electronic chip that records each time
a patient opens the bottle. This method has various advantages over subjective and
other measures. Over estimation of self-reported adherence and pill dumping can be
detected by this method. Additionally, this method also provides the time and date the
pill bottle was opened each time. However, the cost of these high-tech devices is a
problem for some investigators. Moreover, patient may open the bottle but not ingest
the medicine. Some patients make a cache of medicine to be taken at office. This may
not be recorded by this measure.

The Importance of Health-related Quality of Life:

The term "quality of life" was first used in 1943, in a novel about working in aircraft
factory. However, it became popular with social scientists in the 1970' s, as US cities
and states tried to rate the "quality of life" they offered. World Health Organization
(WHO) Quality of Life group defines quality of life as "an individual' s perception of
their positions in the life in context of the culture and value systems in which they live

9

and in relation to their goals, expectations, standards and concerns. Quality of life is an
evaluation of all aspects of life including, health, education, family life, community,
housing, friendship, marriage, nation, neighborhood, standard of living, and work.
Some authors also add spiritual security to the list of domains affecting quality of life.
Health is one of the domains that affect our quality of life. WHO defined health in its
constitution as "The state of optimum, physical, mental, and social well-being, and not
merely the absence of disease or infirmity." The term health-related quality of life
(HRQoL)

encompasses multiple dimensions,

including physical

functioning,

psychological state, general health status, family situational interaction, social ability,
and somatic sensation.

The measurement of HRQoL is becoming an increasingly common activity m
healthcare systems around the world. These measurements are taken for variety of
reasons including, as indicators of population health status, outcome measures in
clinical trials, in economic evaluation of new technologies, and in some ,cases, for
individual patient management. There are two basic approaches to measuring HRQoL.
The first involves use of generic instruments that measure broad aspects of HRQoL.
These instruments are not designed to assess HRQoL relative to particular medical
condition, but rather to provide a general sense of the effects of an illness. Medical
outcomes study Short-Form Health Survey (SF-36) is an example of generic HRQoL
instrument. It measures HRQoL along 8 different domains: physical functioning, role
limitation due to physical problems, bodily pain, general health, vitality, social
functioning, role limitation due to emotional problems, and mental health. It assesses
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both physical and mental health scores of the individual and measures both positive
and negative aspects of Physical and Mental Health [33].

Generic measures can be administered to different populations to examine the impact
of various healthcare/therapeutic programs on HRQoL. These measures allow for
comparisons of HRQoL across a variety of medical conditions. The major limitation
of generic instruments is that may not be sensitive enough to detect subtle treatment
effects specific to a particular disease.

The second approach involves the use of instruments that are specific to a disease
(e.g., osteoporosis), a population (e.g., the elderly), or clinical problem (e.g. , pain).
These measures are more sensitive towards specific disease or population, and
therefore to have greater relevance to practicing clinician. The Arthritis Impact
Measurement Scale (AIMS) is an example of disease-specific instrument that
measures HRQoL specific to arthritis.

Information about Quality of life of patients gathered systematically and routinely
directly before consultation could be integrated in complex medical decision-making
process [34]. Health related quality of life has been shown to be related with patient
satisfaction and the main determinants of the health service quality improvement [35].

Health-related quality of life or biologic outcome of treatment might predict adherence
to HIV medication. The correlation between HRQoL and adherence is complex and
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merits careful study [36]. Many authors have reported the impact of HRQoL on
patient's ability to adhere to treatment. Quality of life (QoL) may be an important
consideration in maximizing treatment consideration in Hepatitis patient [37]. Suboptimal patient adherence was shown to be related to inadequate viral suppression
[38]. Previous research suggests that patients with higher symptoms (poor physical
health) and depression are more likely to be non-adherent to medications [21, 39]. The
patients with better quality of life, do feel better about themselves and world, and are
more likely to be adherent. Research data also supports the belief that survival and
biomedical outcomes increase when the patient's perception of the impact of treatment
on quality oflife is taken into consideration [40].

Most Highly Active Anti-Retroviral Treatment (HAART) regnnens are far from
convenient for patients. HAART may have negative impact on patient's quality of life
[41]. Short-term and long-term toxicities frequently occur which may have negative
impact on the patient's Health-related quality of life (HRQoL). In addition, need for
strict adherence to substantial number of pills, rigid time schedule, and dietary
prescription may interfere with patient's daily activity. In patients with symptomatic
HIV infection or AIDS, opportunistic infection could significantly affect HRQoL. In
addition, social stigma ,associated with the disease and associated pain caused
interferes with patient's ability to perform daily activities. It is therefore assumed that
most people infected with HIVI AIDS do not feel well and that disease has an effect on
their quality of life.
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METHODOLOGY

Study Design:
The original study was conducted by Dr Cynthia Willey, Professor, Department of
Pharrnacoeconomics and Pharrnacoepidemiology, University of Rhode Island, during
the year 1995-98. The purpose of the original study was to develop measure of stages
of change for medication adherence. National Institute of Health (NIH) funded the
study. This is a descriptive cross-sectional study of self-reported adherence to
prescribed HN medication adherence.
Sample Population:
The sample consisted of 145 patients who responded to the survey. All individuals
were infected with HIV and currently prescribed approved HN medication. The
sample comprised 71 % males and 29% females . The patients were aged between the
ages 24-57. Mean age was 39. The sample comprised 62% whites and 38% nonwhites. Average level of education was 12 years.

Data Collection:
The data was collected by administering a standardized self-reported questionnaire to
the subjects to assess the compliance to HIV drugs. Questionnaires were distributed to
the patients in Rhode Island at different sites affiliated with Brown University AIDS
program. These sites include:
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1. The Miriam Hospital Immunology Center: This center serves majority of the
HIV positive women in Rhode Island.
2. Stanley Street Treatment and Resources: This center serves the Greater Fall
River Massachusetts area and provides care to indigent and intravenous drug
users.
3. Veteran Affairs Medical Center in Providence, RI: This center treats
approximately 60 HIV positive men.

The questionnaire covered following aspects:

• Demographic: Age, gender, ethnicity, years of education, living status, and
employment status.

• Economic status: Family income, job, type of health insurance coverage, and
cost of treatment.
•

Coping: ways of coping with HIV.

•

Social support: Social, financial and emotional support provided by family and
friends.

•

Quality of Life: Physical and mental functioning, general health, number of
days spend in hospital in past two weeks, social ability and psychological
health (as measured by SF-36).

•

Medication used: Adherence levels, number of doses missed in past one month
and three months, side effects, etc.
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Measure of Health-related Quality of Life:

HRQoL is generally measured with a collection items, scales and domains. An item is
a single question in an instrument. A domain identifies a particular focus of attention,
like bodily pain, vitality, etc. SF-36 is a reliable, precise, and validated method of
measuring quality of life [33, 42]. There is a strong basis for interpreting SF-36 scales
as measure of health and health-related quality of life. A positive correlation (ranging
from 0.43 to 0.69) has been found between SF-36 scales and general measure of
quality of life [33]. The four domains of physical and mental health were measured for
the purpose of this study. This enabled the production of scores with the same
reliability and validity as those reported here and in other Medical Outcome Studies.
Following set of questions were used to measure four domains of physical and mental
health.
Physical Health:

Two domains of physical health were assessed by using the responses to the following
questions.
1. General Health Status:
Q 1. How would you describe your current health status?

2. Bodily Pain:
Q 1. How much bodily pam have you had during the past four weeks?
Q2. During the past 4 weeks, how much did pain interferes with your normal work
(including both work outside the home and housework)?
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Mental Health:

Two domains of mental health were assessed by using the responses to the following
questions.

1. General Mental Health:
Q 1. During the past 4 weeks, have you been a very nervous person?
Q2. During the past 4 weeks, have you felt so down in dumps that nothing could
cheer you up?
Q3. During the past 4 week, have you been a happy person?
Q4. During the past 4 weeks, have you felt downhearted and blue?
Q5. During the past 4 weeks, have you felt calm and peaceful?

2. Vitality/Fatigue:
Q 1. During the past 4 weeks, did you have a lot of energy?
Q2. During the past 4 weeks, did you feel full of prep?
Q3. During the past 4 weeks, did you feel worn out?
Q4. During the past 4 weeks, did you feel tired?

HRQoL scales are scored so that higher score indicates better health state. The scoring
involves following steps:
Data Entry: The responses to all these questions are based on Likert Scale. All the
responses were key punched as coded in the questionnaire. The response options were
coded as 1, 2, 3, 4, and 5.
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(

Item Recoding: All questions were checked for out of range values. All out of range
values were recoded as missing data. The next step after data entry was the recoding
of response choices so that a higher score indicates a better health state. Hereby,
question
#1 to 4 in Mental health and question #3 to 4 were reverse coded so that higher score
indicates better health.
Item Recalibration: Two questions require recalibration to satisfy linear relationship
between item scores (John ware et al, SF-36 health survey, manual and interpretation
guide).
General health: The responses were recoded as suggested in SF-36 scoring manual.
Precoded item Value
1
2
3
4

5

Final Item value
5.0
4.4
3.4
2.0
1.0

Bodily Pain: The recommended recoding for two questions pertaining to bodily pain
was followed. The administration of second question depends on the response to first
question. The two questions in bodily pain had unequal number of response choices.
This recoding method helped to convert second question to a six-level item of roughly
equal variance to first question.
Computing Raw Scores: After item recoding, raw scores were computed for each four
scales i.e. General health, Bodily pain, vitality, and Mental Health individually. The
raw score is the algebric sum of responses for all items in that scale. For example, the
raw scale score for the mental health scale is the sum of the scores for all five
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responses pertaining to general mental health. As recommended, if any respondent has
missed more than one question on any domain, the score for that domain was not
calculated. Finally each raw score was transformed to a 0 to 100 scale using the
formula shown below.
Transformed Score= [CActual raw score - lowest possible raw score)] *100
Possible raw score range

This transformation converts the lowest and highest possible scores to zero and 100,
respectively. This transformation enables comparison of scores with norms derived
from national health surveys and other published and forthcoming results. The scores
were calculated separately for anti-retroviral and protease inhibitors drugs for the ease
in analysis.

Measure of Adherence:

1. Percentage Adherence:
Percentage adherence was calculated separately for anti-retroviral drugs and protease
inhibitors. Percentage adherence in past three months was calculated using two sets of
questions from the questionnaire. The number of doses missed was determined by
using the response to question, "During the past three months, about how many times
did you miss a dose of this medication"? The response to question, "How often do you
take this medication" was used to determine the total number of doses the patient is
supposed to take in three month period.
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Percentage adherence was calculated by dividing total number of doses missed in the
past three month by the total number of prescribed doses using the formula:
Percentage adherence = 1- [ Number of doses missed in past three months ] x 100
Total number of doses in three months
The questionnaire has separate questions for different class of drugs, thus percentage
adherence was calculated separately for anti-retroviral and protease inhibitors drugs.
The average percentage adherence for the past three months was calculated for both
anti-retroviral and protease inhibitors.

No measure of adherence is perfect, and self-reported measures like questionnaires,
often present the disadvantage of over reporting [43]. Although most literature
suggests a cut-off limit of 80% in chronic conditions, successful HN therapy requires
higher level of adherence. The rate of virologic failure sharply increases when less
than 95% of prescribed dose of drug is actually taken [17] . Thus, a cut-off limit of
95% adherence was selected to dichotomize respondents. All patients showing greater
than or equal to 95% adherence were classified as "adherent" and those showing less
than 95% adherence were classified as "non-adherent". The adherents were coded as
"l" and non-adherents were coded as "O".

2. Medication adherence scale: This is a previously validated scale to measure
compliance. It contains six questions that are answered yes or no. Positive response
indicates less medication adherence. A "Yes" was recoded as "l" and a ''No" was
recoded as "2". The aggregate score for each respondent was obtained by taking the
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sum of all six responses. The aggregate score ranged from 6 to 12 with higher score
indicating poor adherence. This scale includes following questions:
•

During the last 3 months, have you ever stopped taking your protease
inhibitor/antiretroviral medication because you felt worse?

• During the last 3 months, have you ever forgotten to take your protease
inhibitor/ antiretroviral medication?
•

During the last 3 months, have you at times been careless about taking your
protease inhibitor/antiretroviral medication?

•

During the last 3 months, have you ever taken less of your protease
inhibitor/antiretroviral medication than your doctor prescribed because you felt
better?

•

During the last 3 months, have you ever taken less of your protease
inhibitor/antiretroviral medication than your doctor prescribed because you felt
worse?

•

Since you began taking protease inhibitors/antiretroviral medications, have you
ever purposely taken more/less of the medication than your physician
prescribed or discontinued your medications?

The MAS scores were calculated separately for Anti-retroviral and protease inhibitor
drugs. The MAS score was not calculated (coded as missing) if any respondent has
missed more than one question in six item scale. Also, the average score of antiretroviral and protease inhibitors were individually calculated. Respondents with a
score of 6 were classified as "adherent" and respondents with a score of more than 6
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were classified as "non-adherent". Thus any respondent who has marked "yes" to at
least one of the six questions was classified as non-adherent. This rather strict cut-off
level of adherence was selected to offset over-reporting of adherence in self-reported
measure.

Statistical Analysis:
Dependent Variable:

•

Adherence to anti-retroviral drugs in the past three months (dichotomous with
95% cut-off level).

• Adherence to protease inhibitors in the past three months (dichotomous with
95% cut-off level)

•
•

Adherence as measured using MAS for anti-retroviral drugs
Adherence as determined using MAS for protease inhibitors .

Independent Variable: On the basis of literature review, these variables were included
in this research. The IVs of primary interest were•

Bodily Pain

•

General Health

•

Mental Health

•

Vitality/Fatigue

Demographic variable:
•

Age (Categorical variable )

< 35 years= 1

2: 35 and< 42 years= 2
:=:: 42 years= 3
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•

Gender (Categorical variable)

Male= 1
Female= 0
•

Ethnicity (Categorical variable)

Whites= 1
Non-whites= 0
•

Years of Education (Categorical variable)

::::_ 12 years= 1

< 12 years= 0
•

IV Drug use (Categorical variable)

Occasionally to regular= 1
Not at all or twice in 6 months= 0
•

CD4 count (Categorical variable)

::: 200= 1
> 200= 0

•

Time since Diagnosis (Categorical variable)

Less than 1 month to 2 years= 1
3 to 4 years= 2
5 years or more= 3
•

Insurance (Categorical variable)

Insured= 1
Uninsured= 0
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• Annual income (Categorical variable)
< $15000= 1
~

$15000= 0

Of these, four domains of QoL are the N s of primary interest. The other variables
may act as confounders. Univariate analyses were run on all dependent and
independent variables. The data was tested for normality, linearity, skewness, and
homoscedasticity. The primary independent variables were categorized into four
categories and logistic regression was run between each independent variables and
each dependent variable to assess parametric form. No linear relation was found
between independent variable and dependent variable. The primary independent
variables were thus categorized into two or three categories for the final model.
Bivariate tests were run between dependent variables and all independent variables
excluding variables of primary interest. Similar bivariate test were also run between
primary independent variables and other independent variables. These include:
1. Chi-square tests were performed between dependent variable i.e. 95% AV, 95%
PI, MAS AV and MAS PI; and other independent variables like, age groups,
gender, race, annual family income, years of education, time since diagnosis,
CD4 count, injection drug use, and insurance.
2. Chi-square tests were performed between each primary independent variable i.e.
GH, BP, V, and MH; and other independent variables like, age, gender, race,
annual family income, years of education, time since diagnosis, CD4 count,
injection drug use, and insurance.
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All categorical variables, which had more than two categories, were dummy coded
for purpose of final logistic model for e.g. The primary independent variable "mental
health" was dummy coded as Low MR-score below 28, Med MR-score between 28
and 40. Patients with MR score more than 40 were treated as reference group. Test
for collinearity was performed between each dependent variable and each
independent variable. No collinearity was detected between any variables. Logistic
model were run between each dependent variable and each independent variable. A
maximum Likelihood ratio test (Chunk test) was performed to assess the
significance of interaction terms in the model. The full model with all interaction
terms and reduced model without interaction terms were compared for its log
likelihood values. Any significant change in value suggested interaction in the
model.

The confounding effect of each independent variable was assessed as described by
David Kleinbaum. Starting with the "Gold model" i.e. model with all independent
variables, each variable was sequentially dropped with replacement and its effect on
the odds ratio and confidence interval was studied. The variables which did not have
any effect on the odds ratio were dropped from the model. Separate models were run
for each primary independent variables due to high correlation between them.
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RESULTS

Table 1: Demographics and Clinical Characteristics of Patient Population on
Anti-retroviral Medication:

Total number of patients on anti-retroviral medication was 137. Age of these patients
was between 24 and 57. The mean age was 38. Males constituted 73.0% of the sample
while females constituted 26.9% of the sample. Majority of the patients were whites.
Native Americans, Hispanics, Asians, African-American, and others together
constituted 35.8% of the population.

Majority of respondents had at least 12 years of education. About 29.0% of the
patients reported that they lived alone while majority of them (70.9%) reported living
with others. 60.5% reported that their annual income was more than $15,000. Majority
of patients also had some kind of insurance, while only 16.0% of patients had no
insurance. 64.6% of the patients had been diagnosed of HN for more than 5 years.
47.6% had a T-cell count of less than 200 and 52.3% of the patients had a T-cell count
of more than 200. Surprisingly, only 3.8% of the patients reported that they used
intravenous drugs, while the majority of patients denied use of intravenous drugs in
past 6 months.

Table 2: Demographics and Clinical Characteristics of Patient Population on
Protease-inhibitor Medication:

Total number of patients on anti-retroviral medication was 77. Age of these patients
was between 24 and 57. The mean age was 38. Males constituted 74.3% of the sample
while females constituted 25.6% of the sample. Majority of the patients were whites.

25

Native Americans, Hispanics, Asians, African-American, and others together
constituted only 22.9% of the population.

Majority of respondents had at least 12 years of education. About 27.0% of the
patients reported that they lived alone while majority of them (72.9%) reported living
with others.57.3% reported that their annual income was more than $15,000. Majority
of patients also had some kind of insurance, while only 12.1 % of patients had no
insurance. 63.5% of the patients had been diagnosed of HIV for more than 5 years.
54.9% had a T-cell count of less than 200 and 45 .1% of the patients had a T-cell count
of more than 200. Interestingly, only 2.6% of the patients reported that they used
intravenous drugs, while the majority of patients denied use of intravenous drugs in
past 6 months.

Table 3: Adherence with Anti-retroviral (A.V.) Medications (Dependent
Variable):

Patients with adherence levels of more than 95% were classified as adherent, while
patients with adherence level of less than 95% were classified as non-adherence.
Using this cut-off, 87.7% (N= 115) of the patients were found to be adherent, while
12.2% (N= 169) were found to be non-adherent.
Medication Adherence Scale reported 42.2% (N= 62) being adherent, while 54.7%
(N=75) reported not being adherent to their medication
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Table 4: Adherence with Protease Inhibitor (P.I.) Medications (Dependent
Variable)

Patients with adherence levels of more than 95% were classified as adherent, while
patients with adherence level of less than 95% were classified as non-adherence.
Using this cut-off, 83.7% (N= 62) of the patients were found to be adherent, while
16.2% (N= 12) were found to be non-adherent.
Medication Adherence Scale showed that 48.0% (N= 37) have bee adherent, while
51.9% (N=40) reported not being adherent to their medication

Table 5: Mean and Range values of Quality of life domains (Primary IV) in
patient on anti-retroviral drugs compared with general US population.
As suggested in the literature, the patients scored significantly below the US general
population on all four scales of Quality of life. This suggests lower physical as well as
mental health reported by HN patients compared to US general population.

Table 6: Mean and Range values of Quality of life domains (Primary IV) in
patients on protease inhibitors compared with general US population.
As suggested in the literature, the patients prescribed protease inhibitors scored
significantly below the US general population on all four scales of Quality of life. This
suggests lower physical as well as mental health reported by HN patients compared to
US general population.
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Table 7: Multiple Chi-Square Tests done on the Adherence to Antiretroviral
Medications with 95% Cut off (Categorical Dependent Variable) and other
Categorical Independent Variables.
Chi square test showed no significant association between the adherence and other
independent variables. This is consistent with past research that has shown that
demographic variables are not associated with HN adherence.

Table 8: Multiple Chi-Square Tests done on the Adherence to Antiretroviral
Medications using MAS (Categorical Dependent Variable) and other Categorical
Independent Variables.
Chi square test showed no significant association between the adherence and other
independent variables. This is consistent with past research that has shown that
demographic variables are not associated with HN adherence.

Table 9: Multiple Chi-Square Tests done on the Adherence to Protease Inhibitor
Medications with 95% cut off (categorical Dependent Variable) and other
Categorical Independent Variables.
Chi square test showed no significant difference between the adherence and other
independent variable except for variable "gender". Males were found to be more
adherent than females .

Table 10: Multiple Chi-Square Tests done on the Adherence to Protease
Inhibitor Medications using MAS (categorical Dependent Variable) and other
Categorical Independent Variables.
The variable "annual family income", and "T-cell count" were found to be
significantly associated with MAS adherence. Patients with annual income more than
$15,000 were found to be more adherent than their poorer counterparts. Similarly,
patients with T-cell count of less than 200 were found to be more adherent than
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patients with T-cell count of more than 200. This is found to be consistent with
previous research.

Table. 11: Multiple Chi-Square tests done on "General Health" (Categorical) and
other Independent Variables (Categorical) for people on anti-retroviral
medication.
The variable "ethnicity" and "annual family income" were found to be significantly
associated with "general health". Whites reported better general health compared to
non-whites. Similarly, patients with annual income greater than $15,000 had better
mean score on general health compared to patients with annual income less than
$15,000.

Table. 12: Multiple Chi-Square tests done on "Bodily Pain" (Categorical) and
other Independent Variables (Categorical) for people on anti-retroviral
medication.
The variable "ethnicity" was found to be significantly associated with "bodily pain".
Whites reported better mean score on bodily pain compared to non-whites. This
difference was significant at a p-value of 0.0327. No other variable of interest show
any significant association with bodily pain.

Table. 13: Multiple Chi-Square tests done on "Vitality/Fatigue" (Categorical)
and other Independent Variables (Categorical) for people on anti-retroviral
medication.
The variable "gender" was found to be significantly associated with "vitality" (pvalue= 0.0047). Females had better score on vitality than their male counterparts. No
other variable show any significant association with vitality.
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Table. 14: Multiple Chi-Square tests done on "Mental Health" (Categorical) and
other Independent Variables (Categorical) for people on anti-retroviral
medication.
No variable show any significant association with the variable "mental health".

Table. 15: Multiple Chi-Square tests done on "General Health" (Categorical) and
other Independent Variables (Categorical) for people on Protease Inhibitors
medication.
The variable "years of education" was found to be significantly associated with
"general health". Patients with more than 12 years of education had better mean score
of general health than patients with less than 12 years of education (p-value= 0.026).

Table. 16: Multiple Chi-Square tests done on "Bodily Pain" (Categorical) and
other Independent Variables (Categorical) for people on Protease Inhibitor
medication.
The variable "annual family income" was found to be significantly associated with
"bodily pain". Patents with annual family income more than $15,000 reported better
mean score on bodily pain compared to patients with annual income less than $15,000.
No other variable of interest show any significant association with bodily pain.

Table. 17: Multiple Chi-Square tests done on "Vitality/Fatigue" (Categorical)
and other Independent Variables (Categorical) for people on Protease Inhibitor
medication:
No variable show any significant association with the variable "vitality/fatigue".

Table. 18: Multiple Chi-Square tests done on "Mental Health" (Categorical) and
other Independent Variables (Categorical) for people on Protease Inhibitor
medication.

The variable "gender" was found to be significantly associated with "mental health".
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Females reported better mental health compared to males (p-value= 0.032). No other
variable of interest show any significant association with bodily pain.

Table. 19: Logistic Regression Analysis between Adherence to Anti-retroviral
Medication with a 95% cut-off (Dependent Variable) and Independent Variables
of Primary Interest.
This table summarizes the final logistic model run between dependent variable (95%
adherence) and each of primary independent variable controlling for the confounding
variables as described by Kleinbaum [44].

Table. 20: Logistic Regression Analysis between Adherence to Anti-retroviral
Medication using MAS (Dependent Variable) and Independent Variables of
Primary Interest.
This table summarizes the final logistic model run between dependent variable (MAS
adherence) and each of primary independent variable controlling for the confounding
variables (as described by Kleinbaum).

Table. 21:
Logistic Regression Analysis between Adherence to Proteaseinhibitor Medication with a 95% cut-off (Dependent Variable) and Independent
Variables of Primary Interest.
This table summarizes the final logistic model run between dependent variable (95 %
adherence) and each of primary independent variable controlling for the confounding
variables. The variable "gender" was found to be significantly associated with both
95% adherence and mental health.
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Table. 22:
Logistic Regression Analysis between Adherence to Proteaseinhibitor Medication using MAS (Dependent Variable) and Independent
Variables of Primary Interest.
This table summarizes the final logistic model run between dependent variable (MAS
adherence) and each of primary independent variable controlling for the confounding
variables. The variable "annual family income" was found to be significantly
associated with both MAS adherence and bodily pain.
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Table 1: Demographics and Clinical Characteristics of Patient Population on
Anti-retroviral Medication:
Demographic
Variables
Age
<35 years
35-41 years
>41 years
Years of Education
<12 years
::::12 years
Gender
Female
Male
Race
Whites
Non-whites:
-Native American
-Hispanic
-Asian
-African American
-others
Living arrangement
Alone
With others
Annual Household
Income
<15,000
> 15,000
Insurance
Some
None

N(%)

39(29.77)
45(34.35)
47(35.88)
43(32.82)
88(67.18)
35(26.92)
95(73.08)
84(64.12)
47(35.88)

38(29.01)
93(70.99)
75(60.48)
49 (39.52)

110(83.97)
21(16.031
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Mean=39.38 Median=38
Min=24 Max=57
S.D.= 7.51
Mean=l2.12 Median=l2
Min=O Max=22
S.D.=2.85

Clinical Variable
Current Health Status
Excellent-Good
Fair-Poor
Time Since Diawosis
<1 month-2years
3-4 years
~ 5 _years
T-cell Count
:S200
>200
IV Drug Use
Never or not in past
6 months
Occasionally

N(%)

100(72.99)
37(27.01)
22(16.92)
24(18.46)
84(64.62)
60(47.62)
66(52.38)
126(96.18)
5_Q.82)
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Table 2: Demographics and Clinical Characteristics of Patient Population on
Protease-inhibitor Medication:
Demographic
Variables
Age
<35 years
35-41 years
>41 years
Years of Education
<12 years
2'._12 _years
Gender
Female
Male
Race
Whites
Non-whites:
-Native American
-Hispanic
-Asian
-African American
-others
Living arrangement
Alone
With others
Annual Household Income
<1 5,000
>1 5,000
Insurance
Some
None

N(%)

18(24.32)
27(36.49)
29(39.19)
17(22.97)
57.Q7.03)
19(25.68)
55(74.32)
57(77.03)
17 (22.97)

20(27.03)
54(72.97)
43(57.33)
32(42.67)
9(12.16)
65(87.84)

35

Mean=39.37 Median=38
Min=24 Max=57
S.D.= 7.44
Mean=l2.88 Median=12
Min=O Max=22
S.D.=3.19

Clinical Variable
Current Health Status
Excellent-Good
Fair-Poor
Time Since Diagnosis
<lmonth-2years
3-4 years
> 5 _years
T-cell Count
::::200
>200
IV Drug Use
Never or not in past
6 months
Occasionally

N(%)

62(80.52)
15(19.48)
13(17.57)
14(18.92)
47(63.51)
39(54.93)
32(45.07)
72(97.40)
2(2.60)
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Table 3: Self-reported Quality of life of patients on antiretroviral medication by
medication adherence:
Primary
Independent
Variable
Low Gen Health
Hig_h Gen Health
Low Bodily Pain
High Bodily Pain
Low Vitality
High Vitality_
Low Mental Health
Hig_h Mental Health

95% Self-reported
Adherence
Non-adherent
Adherent
N(%)
N(%)
6(13.64)
38(86.36)
10(11.49)
77(88.51)
7(11.86)
52(88.14)
9(12.50)
63(87.50)
10(16.67)
50(83.33)
6(8.45)
65(91.55)
5(13.64)
30(86.36)
11(12.49)
85(87.51)

Medication Adherence
Scale
Non-adherent
Adherent
N(%)
N(%)
26(55.32)
21(44.68)
49(54.44)
41(45.56)
33(53.23)
29(46.77)
42(56.00)
33(44.00)
22(56.41)
17(43.59)
53(54.08)
45(45.92)
31(63.27)
18(36.73)
44(50.00)
44(50.00)

Table 4: Self-reported Quality of life of patients on protease inhibitors by
medication adherence:
Primary
Independent
Variable
Low Gen Health
High Gen Health
Low Bodily Pain
Hig_h Bodily Pain
Low Vitality
High Vitality
Low Mental Health
Hig_h Mental Health

95% Self-reported
Adherence
Non-adherent
Adherent
N(%)
N(%)
4(17.39)
19(82.61)
8(15.69)
43(84.31)
6(17.65)
28(82.35)
34(85.00)
6(15.001
7(35.00)
13(65.00)
5(9.26)
49(90.74)
9(25.71)
26(74.29)
3(7.69)
36(92.31)
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Medication Adherence
Scale
Non-adherent
Adherent
N(%)
N (o/tl
11(47.83)
12(52.17)
28(51.85)
26(48.151
14(41.18)
20(58.82)
20(46.51)
23(53.49)
13(65.00)
7(35.00)
27 (47.37)
30(52.63)
14(38.89)
22(61.11)
23(56.10)
18(43.90)

Table 5: Mean and Range values of Quality of life domains (Primary IV) in
patient on anti-retroviral drugs compared with general US population.

. 1 d ru_g_s:
pf
a 1ent son Anf1-ret rovira
QoL Scales
Mean

Std Deviation

Range

General Health

51.29

28.01

5-85

Bodily Pain

38.83

13.64

0-64

Vitality

31.91

13.27

0-55

Mental Health

31.76

9.93

0-60

G enera lUSP o_p_u 1a f 10n:
QoL Scales

Mean

Std Deviation

Range

General Health

71.95

20.34

5-100

Bodily Pain

75.15

23.69

0-100

Vitality

60.86

20.96

0-100

Mental Health

74.74

18.05

0-100
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Table 6: Mean and Range values of Quality of life domains (Primary IV) in
patients on protease inhibitors compared with general US population.

Patients on Protease Inhibitors:
QoL Scales
Mean

Std Deviation

Range

General Health

50.81

27.46

5-85

Bodily Pain

39.08

13.33

0-64

Vitality

33.19

12.40

0-55

Mental Health

32.79

9.91

0-60

G enera IUSP O.J!.U If
a aon:
QoL Scales

Mean

Std Deviation

Range

General Health

71.95

20.34

5-100

Bodily Pain

75 .15

23.69

0-100

Vitality

60.86

20.96

0-100

Mental Health

74.74

18.05

0-100
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Table 7: Multiple Chi-Square Tests done on the Adherence to Antiretroviral
Medications with 95% Cut off (Categorical Dependent Variable) and other
Categorical Independent Variables.
Categorical I.V.

Non-Adherent
N_i%l

Adherent
N_i%l

Chi-square
_p_-value

7(17.95)
6(13.33)
3(6.38)

32(82.05)
39(86.67)
44(93.62)

2.7392
0.2543

5(11.63)
11(12.50)

38(88.37)
77(87.50)

0.0204
0.8862

11(11.58)
5(14.29)

84(88.42)
30(85.71)

0.1736
0.6762

1(4.76)
15(13.64))

20(95.24)
95(86.36)

1.2952
0.2551

15(17.76)
1(2.13)

69(82.14)
46(97.87)

6.9546
0.0084*

5(13.16)
11(11.83)

33(86.84)
82(88.17)

0.0442
0.8329

66(85.71)
43(88.42)

9(14.29)
6(11.58)

0.0017
0.9674

2(9.09)
6(25.00)
8(9.521

20(90.91)
18(75.00)
76(90.48)

4.3973
0.1110

5(8.33)
10(15.15)

55(91.67)
56(84.85)

1.3931
0.2379

1(20.00)
15(11.90)
significant

4(80.00)
111(88.10)

0.2939
0.5877

Age
<35 years
35-41 years
>41 years
Years of Education
<12 years
2: 12 _years
Gender
Male
Female
Insurance
None
Some
Ethnicity
Whites
Non-Whites
Living Arrangement
Alone
With Others
Annual Family Income
<15,000
>15,000
Time Since Diagnosis
<1 month-2 years
3-4 years
> 5years
T-Cell Count
::::200
>200
IV Drug Use
No
Yes
* If a. s_0.05, then p- value is
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Table 8: Multiple Chi-Square Tests done on the Adherence to Antiretroviral
Medications using MAS (Categorical Dependent Variable) and other Categorical
Independent Variables.
Categorical I.V.

Non-Adherent

Adherent

N_i_o/ol

N_tO/tl_

22(52.38)
23(48.94)
30(62.50)

20(47.62)
24(51.06)
18(37.50)

1.9000
0.3867

25(53.19)
50(55.56)

22(46.81)
40(44.54)

0.0697
0.7918

55(56.12)
20(52.63)

43(43.18)
18(47.37)

0.1349
0.7134

12(55.55)
63(54.78))

10(44.45)
52(45.22)

0.0004
0.9837

45(51.72)
30(60.00)

42(48.28)
20l._40.0Q2_

0.8788
0.3488

24(60.00)
51(52.581

16(40.00)
46(47.42)

0.6298
0.4274

27(54.00)
44(55.70)

23(46.00)
35(44.30)

0.0356
0.8503

12(52.17)
14(56.00)
48(55.81)

11(47.83)
11(44.00)
38(44.19)

0.1047
0.9490

42(60.87)
30_{_49.18)

27(39.13)
31(50.82)

1.7903
0.1809

5(100.00)
70(53.03)
significant

0(00.00)
62(46.97)

4.2899
0.0383*

Age
<35 years
35-41 years
>4l_years
Years of Education
<12 years
2:12 years
Gender
Male
Female
Insurance
None
Some
Ethnicity
Whites
Non-Whites
Living Arrangement
Alone
With Others
Annual Family Income
<15,000
2:15,000
Time Since Dia~[!PSis
<l month-2 years
3-4 years
'.'.:: 5 years
T-Cell Count
:::: 200
>200
IV Drug Use
No
Yes
* If a :s_0.05, then p- value is

41

Chi-square
_p_-value
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Table 9: Multiple Chi-Square Tests done on the Adherence to Protease Inhibitor
Medications with 95% cut off (categorical Dependent Variable) and other
Categorical Independent Variables.
Categorical l.V.

Non-Adherent
N_(_%J

Age
<35 years
35-41 years
>41 years
Years of Education
<12 years
2: 12 _years
Gender
Male
Female
Insurance
None
Some
Ethnicity
Whites
Non-Whites
Living Arrangement
Alone
With Others
Annual Family Income
<15,000
>15,000
Time Since Diagnosis
<1 month-2 years
3-4 years
2: 5 years
T-Cell Count
::: 200
>200
IV Drug Use
No
Yes
* If a .:s._0.05, then p- value is

Adherent
N_(_%l

Chi-square
_p_-value

5(27.78)
3(11.11)
4(13.79)

13(72.22)
24(88.89)
25(86.21)

2.4142
0.2991

4(23.53)
8(14.04)

13 (76.47)
49(85 .96)

0.8688
0.3513

6(10.91)
6(31.58)

49(89.09)
13(68.42)

4.4407
0.0351 *

12(18.46)
0(0.00)

53(81.54)
9(100.00)

1.9831
0.1591

1(5.88)
11(19.30)

16(94.12)
46(81.701

1.7347
0.1878

8(14.81)
4(20.00)

46(85.19)
16(80.00)

0.2888
0.5910

8(19.51)
4(12.50)

33(81.49)
28(87.50)

0.6434
0.4225

2(15 .38)
2(14.29)
8(17.02)

11(84.62)
11(85.71)
39(82.98)

0.0674
0.9668

6(15.38)
6(18.75)

33(84.62)
26(81.25)

0.1417
0.7066

1(50.00)
11(15.28)
significant

1(50.00)
61_(84.72)

1.7268
0.1888
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Table 10: Multiple Chi-Square Tests done on the Adherence to Protease
Inhibitor Medications using MAS (categorical Dependent Variable) and other
Categorical Independent Variables.
Categorical I.V.

Non-Adherent

Adherent

NJ.%1

NJ.%1

Chi-square
_!!_-value

11(50.00)
15(55.56)
14(50.00)

11(50.00)
12(44.45)

0.2168
0.8973

10(58.82)
30(50.00)

7 (41.18)
30(50.00)

0.4132
0.5204

28(49.12)
12(63.16)

29(50.88)
7(36.84)

1.1279
0.2886

5(50.00)
35(52.24)

5(50.00)
32(47.76)

0.0175
0.8948

28(48.28)
12(63.16)

30(51.72)
7(36.84)

1.2698
0.2598

12(54.55)
28(50.91 )

10(45.45)
27(49.09)

0.0832
0.7729

26(60.47)
14(43.75)

17(39.53)
18(56.25)

2.0595
0.0151 *

7(46.67)
8(50.00)
25(54.35)

8(53.33)
8(50.00)
21(45.65)

0.2981
0.8615

16(42.11)
24(66.67)

22(57.89)
12(33.33)

4.4904
0.0341 *

1(50.00)
39(52.00)
significant

1(50.00)
36(48.00)

0.0031
0.9954

Age
<35 years
35-41 years
>41 years
Years of Education
<12 years
>12 years
Gender
Male
Female
Insurance
None
Some
Ethnicity
Whites
Non-Whites
Living Arrangement
Alone
With Others
Annual Family Income
<15,000
>15,000
Time Since Dia@osis
<1 month-2 years
3-4 years
> 5 years
T-Cell Count
:s 200
>200
IV Drug Use
No
Yes
* If a :s_0.05, then p- value is

1~50.00)
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Table. 11: Multiple Chi-Square tests done on "General Health" (Categorical) and
other Independent Variables (Categorical} for people on anti-retroviral
medication:
Independent
Poor Health
Good Health
Chi-square
Variables
_I>_-value
NJ_%l
N_(_%l
Age
<35 years
13(33.33)
0.0068
26(66.67)
35-41 years
15(33.33)
30(66.67)
0.9966
>41 _Y.ears
16(34.04)
31(65.96)
Years of Education
<12 years
19(44.19)
24 (55.81)
3.2233
25(28.41)
63(71.59)
0.0726
::'.:12_Y.ears
Gender
Male
29(30.53)
1.0370
66(69.47)
Female
14(40.00)
21(60.00)
0.3085
Insurance
None
10(47.62)
11(52.38)
2.2073
Some
34(30.91)
76(69.09)
0.1374
Ethnicity
22(5.88)
62(94.12)
5.7434
Whites
Non-Whites
22(19.30)
25(81.70)
0.0166
Living Arrangement
11(28.95)
Alone
27(71.05)
0.5167
With Others
33_{_35.48)
60(64.52)
0.4722
Annual Family Income
<15,000
32(42.67)
43(57.33)
4.9097
0.0022*
8(16.33)
41(83.67)
::'.:15,000
IV Drug User
2(40.00)
1.6257
No
3(60.00)
41(32.54)
0.2023
Yes
85(67.46)
Time Since Dia@osis
0-2 years
6(27.27)
16(72.73)
0.5849
3-4 years
9(37.50)
15(62.50)
0.7464
55(65.48)
29_{_34.52)
::'.:5 _Y.ears
T-Cell Count
21(31.82)
45(68.18)
0.0329
S200
40(66.67)
0.8561
20(33.33)
>200
* If a :s_0.05, then p- value is significant
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Table. 12: Multiple Chi-Square tests done on "Bodily Pain" (Categorical) and
other Independent Variables (Categorical) for people on anti-retroviral
medication:
Independent
Poor Health
Variables
N_{O/tl
Age
<35 years
14(35.90)
35-41 years
21(46.67)
24(51 .06)
>41 _years
Years of Education
<12 years
22(51.16)
37(42.05)
>12 _years
Gender
44(46.32)
Male
Female
15(42.86)
Insurance
11(52.38)
None
48(30.91)
Some
Ethnicity
Whites
32(38.10)
Non-Whites
27(57.45)
Living Arrangement
19(50.00)
Alone
With Others
42(43 .01)
Annual Family Income
<15,000
44(58.67)
>15,000
12(24.49)
IV Drug User
No
2(40.00)
57(45.24)
Yes
Time Since Diagnosis
0-2 years
8(36.36)
3-4 years
9(37.50)
42(50.00)
2:5 _years
T-Cell Count
29(48.33)
:::: 200
>200
28(48.33)
*If a :s_0.05, then p- value is significant

Good Health

N_{_%l
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Chi-square
_Q-value

25(64.10)
24(53.33)
23(48.94)

2.0540
0.3581

21 (48.84)
51(57.95)

0.9700
0.3247

51(53.68)
20(57.14)

0.1234
0.7253

10(47.62)
62(69.09)

0.5447
0.4605

52(61.90)
20(42.55)

4.5593
0.0327*

19(50.00)
53(56.99)

0.5324
0.4656

31(41.33)
37(75.511

13.9781
0.0002

3(60.00)
69(54.76)

0.0533
0.8174

14(63.64)
15(62.50)
42(50.00)

2.0461
0.3595

31(51.67)
38(57.67)

0.4430
0.5057

{

Table. 13: Multiple Chi-Square tests done on "Vitality/Fatigue" (Categorical)
and other Independent Variables (Categorical) for people on anti-retroviral
medication:
Independent
Variables
Age
<35 years
35-41 years
>41 years
Years of Education
<12 years
2:12 years

Poor Health

Good Health

NJ.%1

N(%l

19(48.72)
22(48.89)
19(40.43)

20(51.28)
23(51.11)
28(59.57)

0.8536
0.6526

22(51.16)
38(43 .1 8)

21 (48.84)
50(56.82)

0.7412
0.3893

Gender
Male
Female

36(37.89)
23(65.71)

59(62.11)
12(34.29)

7.8997
0.0047*

Insurance
None
Some

9(46.36)
51(42.86)

12(53.67)
59(57.14)

0.0873
0.7676

39(46.43)
21(44.68)

45(53.57)
26(55.321

0.0371
0.8473

15(39.47)
45(48.39)

23(60.53)
48(51.61)

0.8634
0.3528

42(56.00)
16(32.65)

33(44.00)
33(67.35)

6.4888
0.0109*

4(80.00)
56(44.44)

1(20.00)
70(55.56)

2.4492
0.1176

11(27.27)
13(37.50)
35(41.67)

11(72.73)
11(62.50)
49(58.33)

1.4043
0.4995

26(39.39)
31(51.67)

40(60.61)
29(48 .33)

1.9108
0.1669

Ethnicity
Whites
Non-Whites
Living Arrangement
Alone
With Others
Annual Family Income
<15,000
>15,000
IV Drug User
No
Yes
Time Since Diaggosis
0-2 years
3-4 years
2:5 years
T-Cell Count
<200
>200

*If a s_0.05, then p- value is significant
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Chi-square
]!_-value

Table. 14: Multiple Chi-Square tests done on "Mental Health" (Categorical) and
other Independent Variables (Categorical) for people on anti-retroviral
medication:
Independent Variables

Poor
Health

Fair Health

Good
Health

NJ.%1

N_(%~}_

NJ.%1

22(56.41)
21(46.67)
20(42.55)

5(12.82)
12(26.67)
16(34.04}_

4.1061
0.1283

21 (48.84)
42(47.73)

11 (25.58)
22(25.00)

0.0089
0.9248

48(50.53)
14(40.00)

26(27.37)
7(20.00)

2.7903
0.0948

10(47.62)
53(48.18)

4(19.05)
29(26.36)

0.4162
0.5188

41(48.81)
22(46.81)

21(25.00)
12_{_25.53)

0.0070
0.9333

18(47.37)
45(48.39)

8(21.05)
25_{_26.88)

1.5111
0.2191

33(44.00)
28(57.14)

20(26.67)
12(24.49)

0.8399
0.3594

5(100.00)
58(46.03)

0(00.00)
33(26.19)

1.2218
0.2690

9(40.91)
13(54.17)
41_{_48.81:2_

6(27.27)
5(20.83)
22(26.19)

0.4131
0.8134

31(46.97)
31(51.67)

14(21.21)
16(26.67)

1.5551
0.2124

Age
<35 years
12(30.71)
35-41 years
12(26.67)
>41 _years
11(23.40)
Years of Education
<12 years
11(25.58)
>12 _years
24(27.27)
Gender
Male
21(22.11)
Female
14(40.00)
Insurance
None
7(33.33)
Some
28(25.45)
Ethnicity
Whites
22(26.19)
Non-Whites
13(27.66)
Living Arrangement
Alone
12(31.58)
With Others
23(24.73)
Annual Family Income
<15,000
22(29.33)
>15,000
9_{_18.37)
IV Drug User
No
0(00.00)
Yes
35(27.78)
Time Since Diawosis
0-2 years
7(31.82)
3-4 years
6(25.00)
21(25 .00)
2:5 _years
T-Cell Count
:::; 200
21(31.82)
>200
13(21.67)
* If a :s_0.05, then p- value is significant
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Chi-square
p-value

Table. 15: Multiple Chi-Square tests done on "General Health" (Categorical) and
other Independent Variables (Categorical) for people on Protease Inhibitors
medication:
Independent
Poor Health
Variables
NJ.%1
Age
<35 years
8(44.44)
35-41 years
7(25 .93)
>41 years
8(27.59)
Years of Education
<12 years
9(52.94)
14(24.56)
2: 12 _years
Gender
Male
16(29.09)
Female
7(36.84)
Insurance
None
3(33 .33)
Some
20(30.77)
Ethnicity
Whites
15(26.32)
Non-Whites
8(47.06)
Living Arrangement
5(25 .00)
Alone
With Others
18(33.33)
Annual Family Income
<15,000
16(39.02)
6(18.75)
2:15,000
IV Drug User
1(50.00)
No
Yes
22(30.56)
Time Since Diaggosis
0-2 years
5(38.46)
3-4 years
5(35.71)
13(27.66)
2:5 _years
T-Cell Count
10(31 .25)
:s 200
11(28.21)
>200
* If a :s_0.05, then p- value is significant
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Good Health

NJ.%1

Chi-square
_E_-value

10(55.56)
20(74.07)
21(72.41)

2.0009
0.3667

8 (47.06)
43(75.44)

4.9235
0.0265*

39(70.91)
12(63.16)

0.3961
0.5291

6(66.67)
45(69.23)

0.0243
0.8762

42(73 .68)
9(52.94)

2.6303
0.1048

15(75.00)
36(66.671

0.4731
0.4915

25(60.98)
26(81.251

3.5088
0.0610

1(50.00)
50(69.44)

0.3435
0.5578

8(61.54)
9(64.29)

0.7277
0.6950

34_{_72 . 3~

22(68.75)
28(71.79)

0.0782
0.7797

Table. 16: Multiple Chi-Square tests done on "Bodily Pain" (Categorical) and
other Independent Variables (Categorical) for people on Protease Inhibitor
medication:
Independent
Poor Health
Variables
NJ%l
Age
<35 years
10(55.56)
35-41 years
11(40.74)
>41 years
13(44.83)
Years of Education
<12 years
9(52.94)
25(43.86)
::::12 _years
Gender
Male
24(43.64)
10(52.63)
Female
Insurance
None
4(44.44)
20(46.15)
Some
Ethnicity
Whites
24(42.11)
Non-Whites
10(58.82)
Living Arrangement
9(45.00)
Alone
With Others
25(46.301
Annual Family Income
<15,000
25(60.98)
9(28.13)
2:15,000
IV Drug User
1(50.00)
No
Yes
33(45 .831
Time Since Diagrrosis
0-2 years
4(30.77)
3-4 years
7(50.00)
23(48.94)
2:5 years
T-Cell Count
15(46.88)
S200
>200
17(43.59)
* If a :s_0.05, then p- value is significant
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Good Health

NJ%l

Chi-square
1!_-value

8(44.44)
16(59.26)
16(55.17)

0.9784
0.6131

18 (47.06)
32(56.14)

0.4348
0.5096

31(56.36)
9(47.37)

0.4601
0.4976

5(55.56)
35(53.85)

0.0093
0.9232

33(57.89)
7(41.18)

1.4737
0.2248

11(55.00)
29(53.70)

0.0099
0.9208

16(39.02)
23(71.88)

7.7947
0.0052*

1(50.00)
39(54.17)

0.0136
0.9072

9(69.23)
7(50.00)
24(51.06)

1.4675
0.4801

17(53.13)
22(56.41)

0.0766
0.7819

Table. 17: Multiple Chi-Square tests done on "Vitality/Fatigue" (Categorical)
and other Independent Variables (Categorical) for people on Protease Inhibitor
medication:
Independent
Poor Health
Variables
N_{_%l
Age
<35 years
8(44.44)
35-41 years
6(22.22)
>41 years
6(20.69)
Years of Education
<12 years
6(35.29)
14(24.56)
2:12 _years
Gender
Male
12(21.82)
Female
8(42.11)
Insurance
None
3(33.33)
Some
17(26.15)
Ethnicity
Whites
15(26.32)
Non-Whites
5(29.41)
Living Arrangement
Alone
6(30.00)
With Others
14(25.93)
Annual Family Income
<15,000
14(34.15)
6_(18.75)
2:15,000
IV Drug User
No
1(50.00)
Yes
19(26.39)
Time Since Diagnosis
0-2 years
6(46.15)
3-4 years
4(28.57)
2:5 _years
10_{_21.281
T-Cell Count
7(21.88)
:s 200
>200
13(33.33)
* If a :s__0.05, then p- value is significant
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Good Health
N_{_%l

Chi-square
__p_-value

10(55.56)
21(77.78)
23(79.31)

3.6753
0.1592

11 (64.71)
43(75.44)

0.7648
0.3818

43(78.18)
11(57.89)

2.9469
0.0860

6(66.67)
48(73.85)

0.2066
0.6494

42(73 .68)
12(70.59)

0.0636
0.8008

14(70.00)
40(74.07)

0.1228
0.7260

27(65 .85)
26(81.25)

2.1418
0.1433

1(50.00)
53(73.61)

0.5509
0.4583

7(53.85)
10(71.43)
37_{_78.72)

3.2163
0.2003

25(78.13)
26(66.67)

0.1406
0.2855

Table. 18: Multiple Chi-Square tests done on "Mental Health" (Categorical) and
other Independent Variables (Categorical) for people on Protease Inhibitor
medication:
Independent
Variables
Age
<35 years
35-41 years
>41 _years
Years of Education
<12 years
2:12 years

Poor Health
N(%)

Good Health
N(%)

Chi-square
p-value

12(66.67)
11(40.74)
12(41.38)

6(33.33)
16(59.26)
17(58.62)

3.5822
0.1668

9(52.94)
26(45.61)

8 (47.06)
31(54.39)

0.2820
0.5954

33(60.00)
6_(31.58)

4.5761
0.0324*

6(33.67)
33(50.77)

0.8013
0.3706

28(49.12)
11(64.71)

1.2756
0.2587

9(45.00)
30(55.56)

0.6524
0.4193

20(48.78)
18(56.25)

04018
0.5262

1(50.00)
38(52.78)

0.0060
0.9381

6(46.15)
9(64.29)
24(51.06)

1.0278
0.5981

17(53.13)
20(51.28)

0.0239
0.8771

Gender
Male
22(40.00)
Female
13(68.421
Insurance
None
3(33.33)
Some
32(49.23)
Ethnicity
Whites
29(50.88)
Non-Whites
6(35.29)
Living Arrangement
Alone
11(55.00)
With Others
24(44.44)
Annual Family Income
<15,000
21(51.22)
>15,000
14(43.75)
NDrugUser
1(50.00)
No
Yes
34(47.221
Time Since Diagnosis
0-2 years
7(53.85)
3-4 years
5(35.71)
>5 years
23(48.94)
T-Cell Count
15(46.88)
:::: 200
>200
19_(48.721
*If a :s_0.05, then p- value is significant
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Table. 19: Logistic Regression Analysis between Adherence to Anti-retroviral
Medication with a 95% cut-off (Dependent Variable) and Independent Variables
of Primary Interest
Independent Variables

General Health (high= 1, low=O)
Gender (M=l, F=O)

Odds
Point
estimate
0.778
0.753

ratio
95% C.I.

Para
estimate

0.19-3.10
0.21-3.60

-0.251
-0.284

Wald
pvalue
0.7219
0.6540

Education (2:12yrs=l, <12yrs=O)

1.056

0.28-3 .86

-0.054

0.9344

Family Income
(<15,000=1, >15,000=0)
Ref-Low diag time (<2 yrs)
Med diag time (3-4yrs=l, else=O)
High diag time (2:5 yrs=l, else=O)
T-cell Count (:S200= 1, >200=0)

0.792

0.212-2.87

-0.233

0.7225

0.330
1.425
1.458

0.05-1.98
0.25-7.84
0.42-4.99

0.109
0.354
0.376

0.2258
0.6840
0.5487

0.972

0.28-3.31

-0.027

0.9644

1.153
3.401
1.103

0.32-4.04
0.61-18.78
0.29-3.61

0.142
0.223
0.036

0.8241
0.1600
0.9543

1.387

0.41-4.66

0.327

0.5966

2.421
0.940
1.041

0.66-8.81
0.26-3.38
0.30-3.61

0.884
-0.061
0.041

0.1799
0.9249
0.9479

0.323
1.311
1.630

0.05-1.94
0.23-7.36
0.46-5.68

-1.131
0.270
0.488

0.2168
0.7584
0.4424

0.289
0.228

0.29-2.83
0.27-1.94

-1.241
-1.478

0.2863
0.1766

1.045
2.837
0.973

0.29-3.66
051-15.58
0.29-3.21

0.043
1.048
-0.012

0.9457
0.2307
0.9838

1.490

0.43-5.01

0.398

0.5257

Bodily Pain (high=l, low=O)
Ref-Low age (<35yrs)
Med age (35-41yrs=l, else=O)
H!_g_h a_g_e (>41_1'.!:_s=l, else=O)
Family Income
(<15,000=1, 2:15,000=0)
T-cell Count (:S200= 1, >200=0)
Vital~Fat!.g_ue

(hi_g_h= 1, low=O)
Gender (M=l, F=O)
Family Income
(<15,000=1, 2:15,000=0)
Ref-Low diag time (<2 yrs)
Med diag time (3-4yrs=l, else=O)
High di'!S_ time (2:5 yrs= 1, else=O)
T-cell Count (:S200= 1, >200=0)

Mental Health
Ref-HighMH
Low MH = 1, else=O
Med MH = 1, else=O
Ref-Low age (<35yrs)
Med age (35-41yrs=l, else=O)
Hig_h ~e (>4b'!:_s=l, else=O)
Family Income
(<15,000=1, 2:15,000=0)
T-cell Count (:S200= 1, >200=0)
* If a s_0.05, then p- value is significant
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Table. 20:
Logistic Regression Analysis between Adherence to Protease
Inhibitors with a 95% cut-off (Dependent Variable) and Independent Variables
of Primary Interest
Independent Variables

Odds ratio
Point
95% C.I.
estimate

Para
estimate

Wald
pvalue

General Health (hig_h= 1, low=O)
Gender (M=l, F=O)

1.788
0.214

0.36-8.75
0.04-0.96

0.581
-1.539

0.4735
0.0451

Race (whites=l, others=O)

0.200

.02-1.94

-1.608

0.1659

Living Status (alone=l, other=O)

0.412

0.08-2.11

-0.886

0.2855

Family Income
(<15,000=1, >15,000=0)
T-cell Count (::::200=1, >200=0)

0.870

0.18-4.16

-0.136

0.8658

1.252

0.30-5.19

0.225

0.5764

Bodi~ Pain (hi_g_h= 1, low=O)
Living Status (alone=l, other=O)

0.999
0.709
0521

0.26-3.73
0.17-2.96
0.12-2.17

-0.001
-0.343
-0.652

0.9986
0.6378
0.3709

1.543

0.39-5.98

0.433

0.5307

Vitality/ Fat!g_ue _{_hi_g_h=l, low=Ol
Gender (M=l, F=O)
Race (whites=l, others=O)
Education (~12_2'.!:_s=l, <12_2'.!:_s=O)
Family Income
(<15,000=1, ~15,000=0l

4.482
0.310
0.185
1.954
0.921

1.10-18.13
0.07-1.30
0.19-1.83
0.42-9.02
0.21-4.01

1.500
-1.171
-1.688
0.670
-0.082

0.0354
0.1108
0.1469
0.3901
0.9126

Mental Health (hi_g_h= 1, low=O)
Gender (M=l, F=O)
T-cell Count (S200=1, >200=0)
* If a< 0.05, then p- value is significant

3.382
0.327
1.175

0.79-14.38
0.08-1.26
0.31-4.42

1.218
-1.119
0.161

0.0990
0.1045
0.8117

Family Income
_{_<15,000=1, ~15,000=0)
T-cell Count ( S200=1, >200=0)
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Table. 21: Logistic Regression Analysis between Adherence to Anti-retroviral
drugs using MAS Scale and Independent Variables of Primary Interest
Independent Variables

Odds ratio
Point
95%
estimate C.I.

Para
estimate

Wald
pvalue

General Health (hig_h=l, low=O))
Race (whites=!, others=O)
Family Income
(<15,000=1, >15,000=0)
T-cell Count (_:s200=1, >200=0)

0.948
1.246
0.827

0.41-2.18
0.56-2.76
0.38-1.78

-0.053
0.219
-0.189

0.9008
0.5889
0.6298

1.743

0.83-3.64

0.555

0.1392

Bodily Pain i_hi_g_h=l, low=O)
Family Income
(<15,000=1, ::::15,000=0)
T-cell Count (S200= 1, >200=0)

0.623
0.687

0.28-1.36
0.30-1.53

-0.472
-0.375

0.2371
0.3593

1.726

0.82-3.80

0.545

0.1458

1.136
1.625

0.52-4.47
0.80-3.27

0.127
0.485

0.7473
0.1744

1.836

0.81-4.13

0.607

0.1421

1.019
0.542
0.744
0.841

0.40-2.54
0.20-1.44
0.32-1.72
0.39-1.80

0.019
-0.613
-0.295
-0.173

0.9672
0.2209
0.4913
0.6567

1.891

0.87-4.01

0.636

0.1075

Vital~

Fat!_g_ue (high=l, low=O)
T-cell Count (_:s200= 1, >200=0)

Mental Health (high=l, low=O)
Ref-Low age (<35yrs)
Med age (35-41yrs=l, else=O)
H!&h a_g_e (>41_2'!'5= 1, else=O)
Livin_g_ Status (alone= I, other=O)
Family Income
(<15,000=1, ::::I5,000=Q2_
T-cell Count (_:s200=1, >200=0)
* If a :s_0.05 , then p- value is significant
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Table. 22:
Logistic Regression Analysis between Adherence to Protease
Inhibitors using MAS Scale and Independent Variables of Primary Interest
Independent Variables

General Health (hi_g_h= 1, low=O)
Ref-Low age (<35yrs)
Med age (35-4lyrs=l, else=O)
High age (>4lyrs=l, else=O)
Race (whites=l, others=O)
T-cell Count (S200= 1, >200=0)
Bodi~ Pain

(hi_g_h= 1, low=Ol
Gender (M=l, F=O)
Race (whites=l, others=O)
-F amily Income
(<15,000=1, 2:15,000=0)
T-cell Count (S200= 1, >200=0)
Vitali_9'!Fat~ue

(hi_g_h= 1, low=O)
Ref-Low age (<35yrs)
Med age (35-41yrs=l, else=O)
High ag_e (>4lY!"_s=1, else=O)
Race (whites=l, others=O)
Family Income
(<15,000=1, >15,000=0)
T-cell Count (S200=1, >200=0)

Mental Health (high=l, low=O)
Ref-Low age (<35yrs)
Med age (35-41yrs=l, else=O)
High ~e _i>4b'.!:_s=1, else=Ol
Race (whites=l, others=O)
Education (2:12-1'.!:_s=l, <12__TI_s=O)
Family Income
_(_<15,000=1, 2:15,000=0)
T-cell Count (S200=1, >200=0)
* If a s_0.05, then p- value is significant

Odds ratio
Point
95%
estimate C.I.

Para
estimate

Wald
pvalue

0.962

0.29-3.19

-0.038

0.9499

1.013
0.739
2.719
3.500

0.28-3.58
0.20-2.67
0.74-9.93
1.26-9.71

0.013
-0.302
1.000
1.252

0.9839
0.6453
0.1305
0.0161

1.241
0.797
2.241
0.399

0.42-3.59
0.23-3.72
0.62-7.71
0.13-1.20

0.2163
-0.2263
0.8070
-0.9184

0.6900
0.7184
0.2004
0.1021

3.381

1.14-10.03

1.2183

0.0281

2.468

0.67-9.02

0.903

0.1720

0.591
0.374
2.248
0.311

0.15-2.29
0.08-1.16
0.60-8.35
0.10-0.96

-0.526
-0.984
0.810
-1.168

0.4466
0.1868
0.2238
0.0423

4.884

1.47-16.18

1.586

0.0095

2.849

0.92-8.73

1.046

0.0690

0.542
0.336
2.393
1.823
0.274

0.27-1.22
0.14-1.02
0.64-9.12
0.49-6.70
0.08-0.87

-0.613
-1.090
0.872
0.600
-1.295

0.3872
0.1520
0.2032
0.3663
0.0290

4.931

1.50-16.44

1.595

0.0094
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DISCUSSION

Adherence is an important factor to achieve the best outcomes in HN disease
management [14]. Strict adherence to medication regimen in HN therapy is important
for maintaining low viral loads. The purpose of this study was to assess HRQoL as a
predictor of medication adherence. Medication adherence scale and percentage
adherence were used as measures of adherence in this study. A rather strict 95% cutoff mark was selected to define adherence based on recent studies and literature
review [17, 45]. Given the complexities of HN therapy and viral response, the
alternative to strict adherence for many patients could be death.

Various factors affect patient's ability and desire to adhere to medication regimens.
Two demographic factors, namely "gender" and "annual family income", were found
to be associated with 95% adherence and MAS adherence respectively in patients
taking protease inhibitors. Males reported more adherence compared to females. This
could be because HN positive females might feel more depressed, anxious, and
distressed than HIV positive males [46]. Similarly, patients with high family income
reported more adherence compared to patients with low family income. This
association is difficult to interpret, as the cost per prescription is not known. Although
wealthy patients have more financial access to medications then low-income patients,
this advantage is offset by prescription coverage available to poor patients through
Medicaid.

No other meaningful association was found between any other

demographic variable (age, years of education, living status, ethnicity, duration of
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illness, etc) and medication adherence in anti-retroviral or protease inhibitor drugs.
This is consistent with previous studies and research [39, 47]. Any inconsistency could
be explained by study limitations discussed later.

In recent years, interest has increased in the measurement of HRQoL, in relation to

health-care. In a chronic disease like HN, the patients' physical and mental health is
significantly affected. The opportunistic infections experienced by AIDS patients
often have detrimental effect on their physical and mental health. Fatigue, emotional
and psychological stress is often associated with HN infection. In this study, many
demographic and clinical factors were found to be associated with HRQoL domains.

For patients on anti-retroviral medications: Physical health domains like "general
health" and "bodily pain" were significantly associated with "ethnicity". Whites
reported better "general health" and lower "bodily pain" than non-whites. Patients
with high annual family income reported better general health and vitality that patients
with annual family income of less than $15,000. This is consistent with Center for
Disease Control findings [48]. Also, males reported better vitality and low fatigue than
females. Previous research also confirms similar difference in perceived quality of life
between males and females [33, 49].

For patients on protease inhibitors: "Years of education" and "annual family
income" were significantly associated with both "general health" and "bodily pain".
Patients with higher level of education and annual family income of more than
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$15,000 reported better general health and low bodily pain than their counterparts.
This could be because educated people are less likely to adopt risk-taking behavior
such as smoking, drugs, and unprotected sex [48]. Also, education and family income
increases self-esteem and confidence, life opportunities and social support. It allows
people to adopt healthier lifestyle and seek better treatment. As with patients on antiretroviral medications, gender was found to be significantly associated with "mental
health" in patients on protease inhibitors.

The patients in this study scored significantly lower on all domains of HRQoL than
general US population (Results: Table 5 & 6). This suggests low HRQoL of HN
patients. The results of this study indicate that "vitality/fatigue" is a significant
predictor of medication adherence in patients taking protease inhibitors. However, no
other domain of HRQoL showed any meaningful association with medication
adherence. Patients with high vitality score were found to be more adherent and
patients with low vitality score were found to be less adherent to their medication.
This is consistent with the results of previous studies, which suggest association of
poor mental health, particularly depression, with medication adherence [39].
Although, other domains of quality of life, especially physical health, were expected to
be associated with medication adherence, the result of the study does not confirm the
same. The limitations of the study could have affected results significantly.
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Limitations:
Measurement of adherence: There is no way to measure adherence in the outpatient

setting with absolute precision and accuracy [50]. Although no measure of adherence
is perfect, self-reporting method, often, tends to overestimate medication adherence.
Recall bias and patients subjectivity often influence patients responses to questions.
This could lead to inaccurate statistical analysis and inaccurate results.

Sample: A sample population of 145, although fairly large, could have led to

sampling errors. Sex, IV drug users and race distribution was not typical of HIV
population. The center for Disease control and prevention (CDC) reported that 18%
were women; in this sample 27% of patients were women. The CDC reported 35% as
intravenous drug users; in this sample only 4.3% reported IV drug use. The CDC
reported 41 % White, 38% Black, 19% Latinos and 1% Asians. Many variables were
found to be skewed. Statistical techniques were used to rectify this shortcoming.

The data was collected in 96-97, when combination therapies were recently
introduced. This study precedes many currently available anti-retroviral drugs and
HAART. Thus, the results of this study may not be generalizable to today.
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CONCLUSION

Though overestimation of self-reported medication adherence cannot be ruled out,
patients in this study group reported good level of adherence. Approximately 85% of
the patients were adherent based on 95% cut-off limit. This high level of adherence is
necessary for the successful management of HIV. In-contrast, MAS showed that only
55% of the patients were adherent to their medication. One of the mental health
domains i.e. vitality/fatigue was found to be significantly associated with 95% self
reported adherence in patients taking protease inhibitors. This study confirms that
patients with good mental health are more likely to adhere to their medication
regimen, using 95% cut-off adherence in patients taking protease inhibitors.

All HIV patients scored considerably low on all health domains when compared with
US general population. Interestingly, HIV patients scored lower on all domains when
compared with medical conditions like diabetes, hypertension, arthritis, CHF, and
clinical depression [33]. These scores suggest that HIV patients suffer from strong
physical and mental impairments, and have low quality of life. Stable demographic
factors, like sex, race, years of education, and annual income were found to predict
HRQoL. These factors precede medication adherence. The society as well as public
health professionals should take a note of this, designing new policies and
interventions to improve patient's HRQoL.
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Many clinicians and clinical investigators now recogmse the importance of
incorporating HRQoL into their routine clinical practice and into clinical studies. One
of the aims of treating patients is to make them feel better and to function better in
their day-to-day activities. This would positively change their beliefs and perceptions
about disease and importance of treatment. The findings of this study could help us in
designing interventions to enhance adherence. Improving quality of life, particularly
controlling depression and improving vitality, appears to be the key for better
medication adherence.
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APPENDIX
/*SAS PROGRAM TO MEASURE ADHERENCE USING 95% CUT-OFF
LIMTI FOR PATIENTS ON ANTI-RETROVIRAL DRUGS*/
options nocenter linesize=72;
libname rak:esh 'c:\Windows\Desktop\rakesh';
data rakesh 1;
set rakesh.hivsurv;
if qiilx= 'bactrim' then qiilx2a=O;
if qii 1x= 'acyclovir' then qii 1x2a=O;
if qiilx= 'pentamidine' then qiilx2a=O;
if qiilx= 'zoloft' then qiilx2a=O;
if qiilx= 'crixivan' then qiilx2a=O;
if qiilx= 'ritonavir' then qiilx2a=O;
if qiilx= 'saquinavir' then qiilx2a=O;
if qiilx2a=O then qiilxl4=.;
if qii lxl4=99 then qiilx2a=.;
if qii lx2a=l then qii lx2a=24;
if qii lx2a=2 then qii lx2a=36;
if qiilx2a=3 then qiilx2a=45;
if qiilx2a=4 then qiilx2a=90;
if qiilx2a=5 then qiilx2a=180;
if qiilx2a=6 then qiilx2a=270;
if qii 1x2a=7 then qii 1x2a=360;
if qiilx2a=8 then qiilx2a=450;
medl= qiilxl4/qiilx2a;
compl=l-medl;
percomp 1=comp1*100;
if qii2x= 'dapsone' then qii2x2a=O;
if qii2x= 'leucovorin' then qii2x2a=O;
if qii2x= 'ms contin' then qii2x2a=O;
if qii2x= 'bactrim' then qii2x2a=O;
if qii2x= 'theodur' then qii2x2a=O;
if qii2x= 'crixivan' then qii2x2a=O;
if qii2x= 'saquinavir' then qii2x2a=O;
if qii2x= 'indinavir' then qii2x2a=O;
if qii2x= 'litonavir' then qii2x2a=O;
if qii2x2a=O then qii2xl4=.;
if qii2xl4=99 then qii2x2a=.;
if qii2x2a=l then qii2x2a=24;
if qii2x2a=2 then qii2x2a=36;
if qii2x2a=3 then qii2x2a=45;
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if qii2x2a=4 then qii2x2a=90;
if qii2x2a=S then qii2x2a=180;
if qii2x2a=6 then qii2x2a=270;
if qii2x2a=7 then qii2x2a=360;
if qii2x2a=8 then qii2x2a=450;
med2= qii2x 14/qii2x2a;
comp2=1-med2;
percomp2=comp2 *100;
if qii3x= 'acyclovir' then qii3x2a=O;
if qii3x= 'bactrim' then qii3x2a=O;
if qii3x= 'biaxin' then qii3x2a=O;
if qii3x= 'clotrimazole' then qii3x2a=O;
if qii3x= 'compazine' then qii3x2a=O;
if qii3x= 'dapsone' then qii3x2a=O;
if qii3x= 'diltiazem' then qii3x2a=O;
if qii3x= 'fluconazole' then qii3x2a=O;
if qii3x= 'mellaril' then qii3x2a=O;
if qii3x= 'minocycline' then qii3x2a=O;
if qii3x= 'motrin' then qii3x2a=O;
if qii3x= 'oxandrin' then qii3x2a=O;
if qii3x= 'vasotec' then qii3x2a=O;
if qii3x= 'zantac' then qii3x2a=O;
if qii3x= 'zovirax' then qii3x2a=O;
if qii3x= 'crixivan' then qii3x2a=O;
if qii3x= 'indinavir' then qii3x2a=O;
if qii3x= 'invirase' then qii3x2a=O;
if qii3x= 'norvir' then qii3x2a=O;
if qii3x= 'ritonavir' then qii3x2a=O;
if qii3x= 'saquinavir' then qii3x2a=O;
if qii3x2a=O then qii3x14=.;
if qii3x14=99 then qii3x2a=.;
if qii3x2a=1 then qii3x2a=24;
if qii3x2a=2 then qii3x2a=36;
if qii3x2a=3 then qii3x2a=45;
if qii3x2a=4 then qii3x2a=90;
if qii3x2a=5 then qii3x2a=180;
if qii3x2a=6 then qii3x2a=270;
if qii3x2a=7 then qii3x2a=360;
if qii3x2a=8 then qii3x2a=450;
med3= qii3x14/qii3x2a;
comp3=1-med3;
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percomp3=comp3*100;
if percomp 1=. then percomp 1=O;
if percomp2=. then percomp2=0;
if percomp3=. then percomp3=0;
totcomp= percomp 1+percomp2+percomp3;
ifpercompl=O and percomp2 NE 0 and percomp3 NE 0 then totcomp= totcomp/2;
if percomp 1 NE 0 and percomp2= 0 and percomp3 NE 0 then totcomp= totcomp/2;
if percomp 1 NE 0 and percomp2 NE 0 and percomp3= 0 then totcomp=totcomp/2;
ifpercompl NE 0 and percomp2 NE 0 and percomp3 NE 0 then totcomp=totcomp/3;
if percomp 1 NE 0 and percomp2=0 and percomp3= 0 then totcomp= totcomp;
if percomp 1=0 and percomp2 NE 0 and percomp3= 0 then totcomp= totcomp;
if percomp 1=O and percomp2=0 and percomp3 NE 0 then totcomp= totcomp;
if totcomp=O then delete;
compb=totcomp GE 95;
noncompb=totcomp LT 95;
/*PROGRAM TO CATEGORIZE INDEPENDENT VARIABLES*/
if qi4=l then qi4=l;
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0;
if qi5=0 then qi5=.;
if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29= 1;
if qi29=5 then qi29=2;
if qi29=6 then qi29=3;
if qi29=0 then qi29=.;
if qi31 =O then qi31 =.;
else if qi31 = 1 or qi31 =2 then qi31 =0;
else if qi31= 3 or qi31=4 then qi31=1;
if qvi52= 0 or qvi52=1 then qvi52=1;
else if qvi52= 2 or qvi52=3 then qvi52=0;
if qil GE 24 and qil Lt 35 then qil=l;
else if qil GE 35 and qil LE 41 then qil =2;
elseifqil GT41 thenqi1=3;
ifqi5 LT 12 then qi5=0;
else if qi5 GE 12 then qi5=1;
ifqi19=0 then qi19=.;
if qi 19=1 then qi 19=1;
if qi19=2 then qi19=0;
if qil9=3 then qi19=0;
if qi 19=4 then qi 19=0;
if qi19=5 then qi19=0;
if qi18a=l then qi18a=O;
if qi18a=2 then qi18a=1;
if qi7=1 then qi7=1;

69

else if qi7=2 then qi7=0;
sex=.;
if qi2='f then sex=O;
if qi2='m' then sex=l;
if qi2=0 then sex=.;
Mqil=.;
ifqi1=2 thenMqil=l;
els·e if qi 1=1 or qi 1=3 then Mqi 1=0;
Hqil=.;
ifqi1=3 thenHqil=l;
else if qi1=2 or qil=l then Hqil=O;
Mqi29=.;
if qi29=2 then Mqi29=1;
else if qi29=1 or qi29=3 then Mqi29=0;
Hqi29=.;
if qi29=3 then Hqi29=1;
else if qi29=1 or qi29=2 then Hqi29=0;
/*PROGRAM TO MEASURE HRQoL*I
if qi3=1 then qi3=5.0;
if qi3=2 then qi3=4.4;
if qi3=3 then qi3=3.4;
if qi3=4 then qi3=2.0;
if qi3=5 then qi3=1.0;
if qi24=1 then qi24=6.0;
if qi24=2 then qi24=5.4;
if qi24=3 then qi24=4.2;
if qi24=4 then qi24=3.1;
if qi24=5 then qi24=2.2;
if qi24=6 then qi24=1.0;
if qi25=0 then qi25=.;
if qi25=1 and qi24=99 then qi25=6.0;
if qi25=2 and qi24=99 then qi25=4.75;
if qi25=3 and qi24=99 then qi25=3.5;
if qi25=4 and qi24=99 then qi25=2.25;
if qi25=5 and qi24=99 then qi25=1.0;
if qi25=1 and qi24=1 then qi25=6.0;
if qi25=1 and qi24 GE 2 and qi24 LE 6 then qi25=5;
if qi25=2 and qi24 GE 1 and qi24 LE 6 then qi25=4;
if qi25=3 and qi24 GE 1 and qi24 LE 6 then qi25=3;
if qi25=4 and qi24 GE l and qi24 LE 6 then qi25=2;
if qi25=5 and qi24 GE l and qi24 LE 6 then qi25=1;
if qi26=0 then qi26=6;
if qi26=1 then qi26=5;
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if qi26=2 then qi26=4;
if qi26 GE 3 and qi26 LE 5 then qi26=3;
if qi26 GE 6 and qi26 LE 7 then qi26=2;
if qi26 GE 7 and qi26 LE 28 then qi26=1;
if qi26=99 then qi26=.;
if qi28a=O then qi28a=99;
if qi28b=O then qi28b=99;
if qi28c=O then qi28c=99;
if qi28d=O then qi28d=99;
if qi28e=O then qi28e=99;
if qi28f=O then qi28f=99;
if qi28g=O then qi28g=99;
if qi28h=O then qi28h=99;
if qi28i=O then qi28i=99;
if qi28g=l then qi28g=6;
if qi28g=2 then qi28g=5;
if qi28g=3 then qi28g=4;
if qi28g=4 then qi28g=3;
if qi28g=5 then qi28g=2;
if qi28g=6 then qi28g=l;
if qi28i=l then qi28i=6;
if qi28i=2 then qi28i=5;
if qi28i=3 then qi28i=4;
if qi28i=4 then qi28i=3;
if qi28i=S then qi28i=2;
if qi28i=6 then qi28i=l;
if qi28b=l then qi28b=6;
if qi28b=2 then qi28b=5;
if qi28b=3 then qi28b=4;
if qi28b=4 then qi28b=3;
if qi28b=5 then qi28b=2;
if qi28b=6 then qi28b=l;
if qi28c=l then qi28c=6;
if qi28c=2 then qi28c=5;
if qi28c=3 then qi28c=4;
if qi28c=4 then qi28c=3;
if qi28c=5 then qi28c=2;
if qi28c=6 then qi28c=l;
if qi28f=l then qi28f=6;
if qi28f=2 then qi28f=5;
if qi28f=3 then qi28f=4;
if qi28f=4 then qi28f=3;
if qi28f=5 then qi28f=2;
if qi28f=6 then qi28f=l;
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;

I

GHr=qi3;
BPr=qi24+qi25;
RPr=qi26;
Vrl =qi28a+qi28e+qi28g+qi28i;
ifVrl GE 117 then Vrl=O;
MHrl =qi28b+qi28c+qi28d+qi28f+qi28h;
ifMHrl GE 123 then MHrl=O;
data rakesh2;
set rakesh 1;
if qi28a=99 then qi28a=(qi28e+qi28g+qi28i)/3;
if qi28b=99 then qi28b=(qi28c+qi28d+qi28f+qi28h)/4;
if qi28c=99 then qi28c=(qi28b+qi28d+qi28f+qi28h)/4;;
if qi28d=99 then qi28d=(qi28b+qi28c+qi28f+qi28h)/4;
if qi28e=99 then qi28e=(qi28a+qi28g+qi28i)/3;
if qi28f=99 then qi28f=(qi28b+qi28c+qi28d+qi28h)/4;
if qi28g=99 then qi28g=(qi28a+qi28e+qi28i/3);
if qi28h=99 then qi28h=(qi28b+qi28c+qi28d+qi28f)/4;
if qi28i=99 then qi28i=(qi28a+qi28e+qi28g/3);
Vr=qi2 8a+qi28e+qi28 g+qi28i;
ifVrl=O then Vr=.;
MHr=qi28b+qi28c+qi28d+qi28f+qi28h;
ifMHrl=O then MHr=.;

GH=(GHr-1)/4*100;
BP=(BPr-2)/1O*100;
RP=(RPr-1)/5*100;
V=(Vr-4)/20*100;
MH=(MHr-5)/25*100;
ifGH LT 60 then GH=O;
else ifGH GE 60 then GH=l;
if BP LT 42 then BP=O;
else if BP GE 42 then BP=l;
ifV LT 35 then V=O;
else ifV GE 35 then V=l;
ifMH LT 28 then MH=O;
ifMH GE 28 and MH LT 40 then MH=l;
else if MH GE 40 then MH=2;
LMH=.;
ifMH=O then LMH=l;
else ifMH=l or MH=2 then LMH=O;
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MMH=.;
ifMH=l then MMH=l;
else if MH=O or MH=2 then MMH=O;
keep Mqil Hqil sex qi4 qi5 qi7 qi18a qi19 Mqi29 Hqi29 qi31 qvi52 GH BP V LMH
MMH compa compb;
/*proc freq;
proc univariate normal plot;
proc freq;
tables MH*qi l/all;
tables MH*sex/all;
tables MH*qi4/all;
tables MH*qi5/a11;
tables MH*qi7/all;
tables MH*qi l 8a/all;
tables MH*qi 19/all;
tables MH*qi29/all;
tables MH*qi3 l/all;*/
proc logistic descending;
model compb = LMH MMH Mqi 1 Hqi 1 qi 19 qi31/ctable pprob=(O to 1 by .1 ) lackfi t
risklimits;
run ;
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/*SAS PROGRAM TO MEASURE ADHERENCE USING 95% CUT-OFF
LIMIT FOR PATIENTS TAKING PROTEASE INHIBITORS*/
options nocenter linesize=72;
libname rakesh 'c:\ Windows\Desktop\rakesh';
data rakeshl;
set rakesh.hivsurv;
if qiilx= 'acyclovir' then qiilx2a=O;
if qiilx= 'pentarnidine' then qiilx2a=O;
if qiilx= 'bactrim' then qiilx2a=O;
if qiilx= 'zoloft' then qiilx2a=O;
if qii lx= '3tc' then qiilx2a=O;
ifqiilx= 'azt' then qiilx2a=O;
if qiilx= 'd4t' then qiilx2a=O;
if qii 1x= 'ddc' then qii 1x2a=O;
if qiilx= 'ddi' then qiilx2a=O;
if qiilx= 'zerit' then qiilx2a=O;
if qiilx= 'epivir' then qiilxla=O;
if qiilx2a=O then qii lx14=.;
if qiilx14=99 then qiilx2a=.;
if qiilx2a=l then qiilx2a=24;
if qii lx2a=2 then qii lx2a=36;
if qii lx2a=3 then qii 1x2a=45;
if qii 1x2a=4 then qii 1x2a=90;
if qiilx2a=5 then qiilx2a=l80;
ifqiilx2a=6 then qiilx2a=270;
if qiilx2a=7 then qii lx2a=360;
if qiilx2a=8 then qiilx2a=450;
medl= qiilx14/qiilx2a;
compl=l-medl;
percompl=compl *100;
if qii2x= 'bactrim' then qii2x2a=O;
if qii2x= 'dapsone' then qii2x2a=O;
if qii2x= 'leucovorin' then qii2x2a=O;
if qii2x= 'ms contin' then qii2x2a=O;
if qii2x= 'theodur' then qii2x2a=O;
if qii2x= '3tc' then qii2x2a=O;
if qii2x= 'azt' then qii2x2a=O;
if qii2x= 'd4t' then qii2x2a=O;
if qii2x= 'ddc' then qii2x2a=O;
if qii2x= 'ddi' then qii2x2a=O;
if qii2x= 'epivir' then qii2x2a=O;
if qii2x= 'zerit' then qii2x2a=O;
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if qii2x2a=O then qii2x14=.;
if qii2x14=99 then qii2x2a=.;
if qii2x2a=l then qii2x2a=24;
if qii2x2a=2 then qii2x2a=36;
if qii2x2a=3 then qii2x2a=45;
if qii2x2a=4 then qii2x2a=90;
if qii2x2a=5 then qii2x2a=l80;
if qii2x2a=6 then qii2x2a=270;
if qii2x2a=7 then qii2x2a=360;
if qii2x2a=8 then qii2x2a=450;
med2= qii2x14/qii2x2a;
comp2=1-med2;
percomp2=comp2 * l 00;
if qii3x= 'acyclovir' then qii3x2a=O;
if qii3x= 'bactrim' then qii3x2a=O;
if qii3x= 'biaxin' then qii3x2a=O;
if qii3x= 'clotrimazole' then qii3x2a=O;
if qii3x= 'compazine' then qii3x2a=O;
if qii3x= 'dapsone' then qii3x2a=O;
if qii3x= 'diltiazem' then qii3x2a=O;
if qii3x= 'fluconazole' then qii3x2a=O;
if qii3x= 'mellaril' then qii3x2a=O;
if qii3x= 'minocycline' then qii3x2a=O;
if qii3x= 'motrin' then qii3x2a=O;
if qii3x= 'oxandrin' then qii3x2a=O;
if qii3x= 'vasotec' then qii3x2a=O;
if qii3x= 'zantac' then qii3x2a=O;
if qii3x= 'zovirax' then qii3x2a=O;
if qiilx= 'azt' then qiilx2a=O;
if qiilx= '3tc' then qiilx2a=O;
if qii 1x= 'd4t' then qii 1x2a=O;
if qiilx= 'epivir' then qiilx2a=O;
if qii3x2a=O then qii3x 14=.;
if qii3x14=99 then qii3x2a=.;
if qii3x2a=l
if qii3x2a=2
if qii3x2a=3
if qii3x2a=4
if qii3x2a=5
if qii3x2a=6
if qii3x2a=7

then qii3x2a=24;
then qii3x2a=36;
then qii3x2a=45;
then qii3x2a=90;
then qii3x2a=180;
then qii3x2a=270;
then qii3x2a=360;
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if qii3x2a=8 then qii3x2a=450;
med3= qii3x14/qii3x2a;
comp3=1-med3;
percomp3=comp3*100;
if percomp 1=. then percomp 1=0;
if percomp2=. then percomp2=0;
if percomp3=. then percomp3=0;
totcomp= percomp 1+percomp2+percomp3;
ifpercompl=O and percomp2 NE 0 and percomp3 NE 0 then totcomp= totcomp/2;
if percomp 1 NE 0 and percomp2= 0 and percomp3 NE 0 then totcomp= totcomp/2 ;
ifpercompl NE 0 and percomp2 NE 0 and percomp3= 0 then totcomp=totcomp/2;
ifpercompl NE 0 and percomp2 NE 0 and percomp3 NE 0 then totcomp=totcomp/3;
if percomp 1 NE 0 and percomp2=0 and percomp3= 0 then totcomp= totcomp;
if percomp 1=O and percomp2 NE 0 and percomp3= 0 then totcomp= totcomp;
if percomp 1=O and percomp2=0 and percomp3 NE 0 then totcomp= totcomp;
if totcomp=O then delete;
compb=totcomp GE 95;
/*PROGRAM TO CATEGORIZE INDEPENDENT VARIABLES*/
if qi4=1 then qi4=1 ;
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0;
if qi5=0 then qi5=.;
if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=1;
if qi29=5 then qi29=2;
if qi29=6 then qi29=3;
if qi29=0 then qi29=.;
if qi31 =0 then qi31 =.;
else if qi31 = 1 or qi31 =2 then qi31 =O;
else if qi31= 3 or qi31 =4 then qi31 =1;
if qvi52= 0 or qvi52=l then qvi52=1;
else if qvi52= 2 or qvi52=3 then qvi52=0;
ifqil GE 24 andqil Lt 35 thenqil =l ;
else if qil GE 35 and qil LE 41 then qil =2;
elseifqil GT 41 thenqi1 =3;
if qi5 LT 12 then qi5=0;
else if qi5 GE 12 then qi5=1;
if qi19=0 then qi19=.;
if qi 19=.1 then qi 19=1;
if qi 19=2 then qi 19=0;
if qi19=3 then qi19=0;
if qi19=4 then qi19=0;
if qi19=5 then qi19=0;
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sex=.;
if qi2='m' then sex=l;
else if qi2='f then sex=O;
if qi7=1 then qi7=l;
else if qi7=2 then qi7=0;
if qi l 8a=l the qi l 8a=O;
if qil8a=2 then qi18a=l;
Mqil=.;
if qi 1=2 then Mqil =1;
else if qi 1=1 or qi 1=3 then Mqi 1=O;
Hqil=.;
if qi 1=3 then Hqil =I;
else if qi 1=2 or qi 1=1 then Hqi 1=O;
Mqi29=.;
if qi29=2 then Mqi29=1;
else if qi29=l or qi29=3 then Mqi29=0;
Hqi29=.;
if qi29=3 then Hqi29=1;
else if qi29=1 or qi29=2 then Hqi29=0;
/*PROGRAM TO MEASURE HRQoL*I
if qi3=1 then qi3=5.0;
if qi3=2 then qi3=4.4;
if qi3=3 then qi3=3.4;
if qi3=4 then qi3=2.0;
if qi3=5 then qi3=1.0;
if qi24=1 then qi24=6.0;
if qi24=2 then qi24=5.4;
if qi24=3 then qi24=4.2;
if qi24=4 then qi24=3.1;
if qi24=5 then qi24=2.2;
if qi24=6 then qi24=1.0;
if qi25=0 then qi25=.;
if qi25=1 and qi24=99 then qi25=6.0;
if qi25=2 and qi24=99 then qi25=4.75;
if qi25=3 and qi24=99 then qi25=3.5;
if qi25=4 and qi24=99 then qi25=2.25;
if qi25=5 and qi24=99 then qi25=1.0;
if qi25=1 and qi24=1 then qi25=6.0;
if qi25=1 and qi24 GE 2 and qi24 LE 6 then qi25=5;
if qi25=2 and qi24 GE 1 and qi24 LE 6 then qi25=4;
if qi25=3 and qi24 GE 1 and qi24 LE 6 then qi25=3;
if qi25=4 and qi24 GE l and qi24 LE 6 then qi25=2;
if qi25=5 and qi24 GE 1 and qi24 LE 6 then qi25=1;
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if qi26=0 then qi26=6;
if qi26=l then qi26=5;
if qi26=2 then qi26=4;
if qi26 GE 3 and qi26 LE 5 then qi26=3;
if qi26 GE 6 and qi26 LE 7 then qi26=2;
if qi26 GE 7 and qi26 LE 28 then qi26=1;
if qi26=99 then qi26=.;
if qi28a=O then qi28a=99;
if qi28b=O then qi28b=99;
if qi28c=O then qi28c=99;
if qi28d=O then qi28d=99;
if qi28e=O then qi28e=99;
if qi28f=O then qi28f=99;
if qi28g=O then qi28g=99;
if qi28h=O then qi28h=99;
if qi28i=O then qi28i=99;
if qi28g=l then qi28g=6;
if qi28g=2 then qi28g=5;
if qi28g=3 then qi28g=4;
if qi28g=4 then qi28g=3;
if qi28g=5 then qi28g=2;
if qi28g=6 then qi28g=l ;
if qi28i=l then qi28i=6;
if qi28i=2 then qi28i=5;
if qi28i=3 then qi28i=4;
if qi28i=4 then qi28i=3;
if qi28i=5 then qi28i=2;
if qi28i=6 then qi28i=l ;
if qi28b=l then qi28b=6;
if qi28b=2 then qi28b=5;
if qi28b=3 then qi28b=4;
if qi28b=4 then qi28b=3;
if qi28b=5 then qi28b=2;
if qi28b=6 then qi28b=l ;
if qi28c=l then qi28c=6;
if qi28c=2 then qi28c=5;
if qi28c=3 then qi28c=4;
if qi28c=4 then qi28c=3;
if qi28c=5 then qi28c=2;
if qi28c=6 then qi28c=l ;
if qi28f=l then qi28f=6;
if qi28f=2 then qi28f=5;
if qi28f=3 then qi28f=4;
if qi28f=4 then qi28f=3;
if qi28f=5 then qi28f=2;
if qi28f=6 then qi28f=l ;
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GHr=qi3;
BPr=qi24+qi25;
RPr=qi26;
Vrl =qi28a+qi28e+qi28g+qi28i;
ifVrl GE 117 then Vrl=O;
MHrl =qi28b+qi28c+qi28d+qi28f+qi28h;
ifMHrl GE 123 then MHrl=O;
data rakesh2;
set rakesh 1;

if qi28a=99 then qi28a=(qi28e+qi28g+qi28i)/3;
if qi28b=99 then qi28b=(qi28c+qi28d+qi28f+qi28h)/4;
if qi28c=99 then qi28c=(qi28b+qi28d+qi28f+qi28h)/4;;
if qi28d=99 then qi28d=(qi28b+qi28c+qi28f+qi28h)/4;
if qi28e=99 then qi28e=(qi28a+qi28g+qi28i)/3 ;
if qi28f=99 then qi28f=(qi28b+qi28c+qi28d+qi28h)/4 ;
if qi28g=99 then qi28g=(qi28a+qi28e+qi28i/3);
if qi28h=99 then qi28h=(qi28b+qi28c+qi28d+qi28f)/4;
if qi28i=99 then qi28i=(qi28a+qi28e+qi28g/3);
Vr=qi28a+qi28e+qi28g+qi28i;
ifVrl=O then Vr=.;
MHr=qi28b+qi28c+qi28d+qi28f+qi28h;
ifMHrl=O then MHr=.;
GR=(GHr- 1)/4*100;
BP=(BPr-2)/10*100;
RP=(RPr-l )/5*100;
V=(Vr-4)/20*100;
MH=(MRr-5)/25*100;
if GR LE 25 then GR=O;
else ifGR GT 25 then GR=l;
if BP LT 42 then BP=O;
else if BP GE 42 then BP=l ;
ifV LE 20 then V=O;
else ifV GT 20 then V=l ;
ifMH LT 36 then MH=O;
else ifMH GE 36 then MH=l ;
keep Mqil Rqil sex qi4 qi5 qi7 qi18a qi19 Mqi29 Rqi29 qi31 qvi52 GR BP V MH
compa compb;
I* proc freq;
proc univariate nonnal plot;
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proc freq;
tables MH*qil/all;
tabl es MH*sex/all;
tables MH*qi4/all;
tables MH*qi5/all;
tables MH*qi7/a11;
tables MH*qi l 8a/all;
tables MH*qil9/all;
tables MH*qi29/all;
tables MH*qi3 l/all;*/
proc logistic descending;
model compb = MH sex qi31 /ctable pprob=(O to 1 by .1 ) lackfit
risklimits;
run;
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/*SAS PROGRAM TO MEASURE ADHERENCE USING MEDICATION
ADHERENCE SCALE FOR PATIENTS ON ANTI-RETROVIRAL DRUGS*/
options nocenter linesize=72;
libname rakesh 'c:\Windows\Desktop\rakesh';
data rakesh 1;
set rakesh.hivsurv;
if qiilx4=0 then qiilx4=99;
if qiilx5=0 then qiilx5=99;
if qiilx6=0 then qiilx6=99;
if qiilx7=0 then qiilx7=99;
if qiilx8=0 then qiilx8=99;
if qiilx9=0 then qiilx9=99;
if qii2x4=0 then qii2x4=99;
if qii2x5=0 then qii2x5=99;
if qii2x6=0 then qii2x6=99;
if qii2x7=0 then qii2x7=99;
if qii2x8=0 then qii2x8=99;
if qii2x9=0 then qii2x9=99;
if qii3x4=0 then qii3x4=99;
if qii3x5=0 then qii3x5=99;
if qii3x6=0 then qii3x6=99;
if qii3x7=0 then qii3x7=99;
if qii3x8=0 then qii3x8=99;
if qii3x9=0 then qii3x9=99;
maslx= qii lx4+qiilx5+qiilx6+qii lx7+qiilx8+qii lx9;
ifmasl GE 109 then masl=O;
mas2x= qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9;
if mas2x GE 109 then mas2=0;
mas3x= qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9;
if mas3x GE 109 then mas3=0;
data rakesh2;
set rakesh 1;
if qiilx4=99 then qiilx4=0;
if qiilx5=99 then qiilx5=0;
if qiilx6=99 then qiilx6=0;
if qiilx7=99 then qiilx7=0;
if qiilx8=99 then qiilx8=0;
if qiilx9=99 then qiilx9=0;
masl =qii lx4+qiilx5+qiilx6+qii lx7+qiilx8+qiilx9;
ifmaslx=O then masl=O;
if qii2x4=99 then qii2x4=0;
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if qii2x5=99 then qii2x5=0;
if qii2x6=99 then qii2x6=0;
if qii2x7=99 then qii2x7=0;
if qii2x8=99 then qii2x8=0;
if qii2x9=99 then qii2x9=0;
mas2=qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9;
if mas2x=O then mas2=0;
if qii3x4=99 then qii3x4=0;
if qii3x5=99 then qii3x5=0;
if qii3x6=99 then qii3x6=0;
if qii3x7=99 then qii3x7=0;
if qii3x8=99 then qii3x8=0;
if qii3x9=99 then qii3x9=0;
mas3=qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9;
if mas3x=O then mas3=0;
if qii 1x= 'bachim' then mas 1=O;
if qiilx= 'acyclovir' then masl =O;
if qii lx= 'pentamidine' then masl =O;
if qii lx= 'zoloft' then mas 1=O;
if qiilx= 'crixivan' then masl=O;
if qiilx= 'ritonavir' then masl =O;
if qii 1x= 'saquinavir' then mas 1=O;
if qii2x= 'bactrim' then mas2=0;
if qii2x= 'dapsone' then mas2=0;
if qii2x= 'leucovorin' then mas2=0;
if qii2x= 'ms contin' then mas2=0;
if qii2x= 'theodur' then mas2=0;
if qii2x= 'crixivan' then mas2=0;
if qii2x= 'saquinavir' then mas2=0;
if qii2x= 'indinavir' then mas2=0;
if qii2x= 'ritonavir' then mas2=0;
if qii3x= 'acyclovir' then mas3=0;
if qii3x= 'bactrim' then mas3=0;
if qii3x= 'biaxin' then mas3=0;
if qii3x= 'clotrimazole' then mas3=0;
if qii3x= 'compazine' then mas3=0;
if qii3x= 'dapsone' then mas3=0;
if qii3x= 'diltiazem' then mas3=0;
if qii3x= 'fluconazole' then mas3=0;
if qii3x= 'mellaril' then mas3=0;
if qii3x= 'minocycline' then mas3=0;
if qii3x= 'motrin' then mas3=0;
if qii3x= 'oxandrin' then mas3=0;
if qii3x= 'vasotec' then mas3=0;
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if qii3x= 'zantac' then mas3=0;
if qii3x= 'zovirax' then mas3=0;
if qii3x= 'crixivan' then mas3=0;
if qii3x= 'indinavir' then mas3=0;
if qii3x= 'invirase' then mas3=0;
if qii3x= 'norvir' then mas3=0;
if qii3x= 'ritonavir' then mas3=0;
if qii3x= 'saquinavir' then mas3=0;
totmas=mas 1+mas2+mas3 ;
if mas 1 NE 0 and mas2 NE 0 and mas3 NE 0 then totmas= totmas/3;
if mas 1 NE 0 and mas2= 0 and mas3 NE 0 then totmas= totmas/2;
ifmasl=O and mas2 NE 0 and mas3 NE 0 then totmas= totmas/2;
if mas 1 NE 0 and mas2 NE 0 and mas3=0 then totmas= totmas/2;
if mas 1 NE 0 and mas2=0 and mas3=0 then totmas=totmas;
if mas 1=0 and mas2 NE 0 and mas3=0 then totmas=totmas;
if mas 1=O and mas2=0 and mas3 NE 0 then totmas=totmas;
if totmas LT 6 then delete;
totmas 1=12-totmas;
iftotmasl = 6 then totmasl=l ;
else if totmasl LT 6 then totmasl = O;
/*PROGRAM TO CATEGORIZE INDEPENDENT VARIABLES*/
if qi4=1 then qi4=1;
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0;
if qi5=0 then qi5=.;
if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=1;
if qi29=5 then qi29=2;
if qi29=6 then qi29=3;
if qi29=0 then qi29=.;
if qi31 =O then qi31 =.;
else if qi31 = 1 or qi31 =2 then qi31 =0;
else if qi31 = 3 or qi31 =4 then qi31 =1;
if qvi52= 0 or qvi52=1 then qvi52=1;
else if qvi52= 2 or qvi52=3 then qvi52=0;
if qil GE 24 and qil Lt 35 then qil =l ;
elseifqil GE 35 andqil LE 41 thenqil =2 ;
elseifqil GT 41 thenqi1=3;
if qi5 LT 12 then qi5=0;
else if qi5 GE 12 then qi5=1;
ifqi19=0 then qi19=.;
if qi 19=1 then qi 19=1;
if qil9=2 then qil9=0;
if qi19=3 then qi19=0;
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(

if qi19=4 then qi19=0;
if qi19=5 then qi19=0;
if qi2=0 then qi2=.;
sex=.;
if qi2='f then sex=O;
if qi2='m' then sex=l;
if qi7=1 then qi7=1;
else if qi7=2 then qi7=0;
if qi 18a=1 then qi 18a=O;
if qi18a=2 then qi18a=l;
Mqil=.;
if qil =2 then Mqil =1;
else if qi 1=1 or qi 1=3 then Mqi 1=0;
Hqil=.;
ifqi1=3 thenHqil=l;
else if qil =2 or qi 1=1 then Hqil =O;
Mqi29=.;
if qi29=2 then Mqi29=1;
else if qi29=1 or qi29=3 then Mqi29=0;
Hqi29=.;
if qi29=3 then Hqi29=1;
else if qi29=l or qi29=2 then Hqi29=0;
/*PROGRAM TO MEASURE HRQoL */
if qi3=1 then qi3=5.0;
if qi3=2 then qi3=4.4;
if qi3=3 then qi3=3.4;
if qi3=4 then qi3=2.0;
if qi3=5 then qi3=1.0;
if qi24=1 then qi24=6.0;
if qi24=2 then qi24=5.4;
if qi24=3 then qi24=4.2;
ifqi24=4 then qi24=3.l;
if qi24=5 then qi24=2.2;
if qi24=6 then qi24=1.0;
if qi25=0 then qi25=.;
if qi25=1 and qi24=99 then qi25=6.0;
if qi25=2 and qi24=99 then qi25=4.75;
if qi25=3 and qi24=99 then qi25=3.5;
if qi25=4 and qi24=99 then qi25=2.25;
if qi25=5 and qi24=99 then qi25=1.0;
if qi25=1 and qi24=1 then qi25=6.0;
if qi25=1 and qi24 GE 2 and qi24 LE 6 then qi25=5;
if qi25=2 and qi24 GE 1 and qi24 LE 6 then qi25=4;
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if qi25=3 and qi24 GE 1 and qi24 LE 6 then qi25=3;
if qi25=4 and qi24 GE 1 and qi24 LE 6 then qi25=2;
if qi25=5 and qi24 GE 1 and qi24 LE 6 then qi25=1;
if qi26=0 then qi26=6;
if qi26=1 then qi26=5;
if qi26=2 then qi26=4;
if qi26 GE 3 and qi26 LE 5 then qi26=3;
if qi26 GE 6 and qi26 LE 7 then qi26=2;
if qi26 GE 7 and qi26 LE 28 then qi26=1;
if qi26=99 then qi26=.;
if qi28a=O then qi28a=99;
if qi28b=O then qi28b=99;
if qi28c=O then qi28c=99;
if qi28d=O then qi28d=99;
if qi28e=O then qi28e=99;
if qi28f=O then qi28f=99;
if qi28g=O then qi28g=99;
if qi28h=O then qi28h=99;
if qi28i=O then qi28i=99;
if qi28g=l then qi28g=6;
if qi28g=2 then qi28g=5;
if qi28g=3 then qi28g=4;
if qi28g=4 then qi28g=3;
if qi28g=5 then qi28g=2;
if qi28g=6 then qi28g=l;
if qi28i=l then qi28i=6;
if qi28i=2 then qi28i=5;
if qi28i=3 then qi28i=4;
if qi28i=4 then qi28i=3;
if qi28i=5 then qi28i=2;
if qi28i=6 then qi28i=l;
if qi28b=l then qi28b=6;
if qi28b=2 then qi28b=5;
if qi28b=3 then qi28b=4;
if qi28b=4 then qi28b=3;
if qi28b=5 then qi28b=2;
if qi28b=6 then qi28b=l;
if qi28c=l then qi28c=6;
if qi28c=2 then qi28c=5;
if qi28c=3 then qi28c=4;
if qi28c=4 then qi28c=3;
if qi28c=5 then qi28c=2;
if qi28c=6 then qi28c=l;
if qi28f=l then qi28f=6;
if qi28f=2 then qi28f=S;
if qi28f=3 then qi28f=4;
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if qi28f=4 then qi28f=3;
if qi28f=S then qi28f=2;
if qi28f=6 then qi28f=l;

GHr=qi3;
BPr=qi24+qi25;
RPr=qi26;
Vrl =qi28a+qi28e+qi28g+qi28i;
ifVrl GE 117 then Vrl=O;
MHrl =qi28b+qi28c+qi28d+qi28f+qi28h;
if MHrl GE 123 then MHrl =O;

data rakesh3;
set rakesh2;
if qi28a=99 then qi28a=(qi28e+qi28g+qi28i)/3;
if qi28b=99 then qi28b=(qi28c+qi28d+qi28f+qi28h)/4;
if qi28c=99 then qi28c=(qi28b+qi28d+qi28f+qi28h)/4;;
if qi28d=99 then qi28d=(qi28b+qi28c+qi28f+qi28h)/4;
if qi28e=99 then qi28e=(qi28a+qi28g+qi28i)/3;
if qi28f=99 then qi28f=(qi28b+qi28c+qi28d+qi28h)/4;
if qi28g=99 then qi28g=(qi28a+qi28e+qi28i/3);
if qi28h=99 then qi28h=(qi28b+qi28c+qi28d+qi28f)/4;
if qi28i=99 then qi28i=(qi28a+qi28e+qi28g/3);
Vr=qi28a+qi28e+q i28 g+qi28i;
ifVrl=O then Vr=.;
MHr=qi28b+qi28c+qi28d+qi28f+qi28h;
if MHr 1=O then MHr=.;
GH=(GHr-1)/4*100;
BP=(BPr-2)/1O*l00;
RP=(RPr-1)/5*100;
V=(Vr-4)/20* 100;
MH=(MHr-5)/25*100;
ifGH LT 60 then GH=O;
else ifGH GE 60 then GH=l;
if BP LT 42 then BP=O;
else if BP GE 42 then BP=l;
if V LE 20 then V=O;
else ifV GT 20 then V=l;
ifMH LT 32 then MH=O;
else if MH GE 32 then MH=l;
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keep Mqil Hqil sex qi4 qi5 qi7 qi l 8a qi l9 Mqi29 Hqi29 qi3 l qvi52 GH BP V MH
totmasl;
/*proc freq;
proc univariate nonnal plot;
proc freq;
tables MH*qi l/all;
tables MH*sex/all;
tables MH*qi4/all;
tables MH*qi5/al1;
tables MH*qi7/all;
tables MH*qil8a/all;
tables MH*qi 19/all;
tables MH*qi29/all;
tables MH*qi31 /all;*/
proc logistic descending;
model totmasl = MH Mqil Hqil qi7 qil9 qi31 /ctable pprob=(O to 1 by .1) lackfit
risklirnits;
run ;
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/*SAS PROGRAM TO MEASURE ADHERENCE USING MEDICATION
ADHERENCE SCALE FOR PATIENTS TAKING PROTEASE INHIBITORS*/
options nocenter linesize=72;
libname rakesh 'c:\Windows\Desktop\rakesh';
data rakeshl;
set rakesh.hivsurv;
if qiilx4=0 then qiilx4=99;
if qiilx5=0 then qiilx5=99;
if qiilx6=0 then qiilx6=99;
if qiilx7=0 then qiilx7=99;
if qiilx8=0 then qiilx8=99;
if qii 1x9=0 then qii 1x9=99;
if qii2x4=0 then qii2x4=99;
if qii2x5=0 then qii2x5=99;
if qii2x6=0 then qii2x6=99;
if qii2x7=0 then qii2x7=99;
if qii2x8=0 then qii2x8=99;
if qii2x9=0 then qii2x9=99;
if qii3x4=0 then qii3x4=99;
if qii3x5=0 then qii3x5=99;
if qii3x6=0 then qii3x6=99;
if qii3x7=0 then qii3x7=99;
if qii3x8=0 then qii3x8=99;
if qii3x9=0 then qii3x9=99;
maslx= qiilx4+qii lx5+qiilx6+qiilx7+qii lx8+qiilx9;
if mas 1x GE 109 then mas 1=O;
mas2x= qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9;
if mas2x GE 109 then mas2=0;
mas3x= qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9;
ifmas3x GE 109 then mas3=0;
data rakesh2;
set rakesh 1;
if qiilx4=99 then qiilx4=0;
if qii 1x5=99 then qii 1x5=0;
if qii 1x6=99 then qii 1x6=0;
if qii 1x7=99 then qii 1x7=0;
if qiilx8=99 then qiilx8=0;
if qiilx9=99 then qiilx9=0;
masl =qii lx4+qii lx5+qiilx6+qii lx7+qii lx8+qii lx9;
ifmaslx=O then masl=O;
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if qii2x4=99 then qii2x4=0;
if qii2x5=99 then qii2x5=0;
if qii2x6=99 then qii2x6=0;
if qii2x7=99 then qii2x7=0;
if qii2x8=99 then qii2x8=0;
if qii2x9=99 then qii2x9=0;
mas2=qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9;
if mas2x=O then mas2=0;
if qii3x4=99 then qii3x4=0;
if qii3x5=99 then qii3x5=0;
if qii3x6=99 then qii3x6=0;
if qii3x7=99 then qii3x7=0;
if qii3x8=99 then qii3x8=0;
if qii3x9=99 then qii3x9=0;
mas3=qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9;
if mas3x=O then mas3=0;

if qii 1x=
if qiilx=
if qii 1x=
if qiilx=
if qii lx=
if qiilx=
if qiilx=
ifqiilx=
if qii 1x=
if qiilx=
if qiilx=

'bactrim' then mas 1=O;
'acyclovir' then masl =O;
'pentamidine' then mas 1=O;
'zoloft' then masl=O;
'3tc' then masl =0;
'azt' then masl=O;
'd4t' then masl =O;
'ddi' then masl=O;
'ddc' then mas 1=O;
'epivir' then masl=O;
'zerit' then masl=O;

if qii2x= 'bactrim' then mas2=0;
if qii2x= 'dapsone' then mas2=0;
if qii2x= 'leucovorin' then mas2=0;
if qii2x= 'ms contin' then mas2=0;
if qii2x= 'theodur' then mas2=0;
if qii2x= '3tc' then mas2=0;
if qii2x= 'azt' then mas2=0;
if qii2x= 'd4t' then mas2=0;
if qii2x= 'ddc' then mas2=0;
if qiilx= 'ddi' then masl=O;
if qiilx= 'epivir' then masl=O;
if qiilx= 'zerit' then masl=O;

89

if qii3x= 'acyclovir' then mas3=0;
if qii3x= 'bactrim' then mas3=0;
if qii3x= 'biaxin' then mas3=0;
if qii3x= 'clotrimazole' then mas3=0;
if qii3x= 'compazine' then mas3=0;
if qii3x= 'dapsone' then mas3=0;
if qii3x= 'diltiazem' then mas3=0;
if qii3x= 'fluconazole' then mas3=0;
if qii3x= 'mellaril' then mas3=0;
if qii3x= 'minocycline' then mas3=0;
if qii3x= 'motrin' then mas3=0;
if qii3x= 'oxandrin' then mas3=0;
if qii3x= 'vasotec' then mas3=0;
if qii3x= 'zantac' then mas3=0;
if qii3x= 'zovirax' then mas3=0;
if qii3x= '3tc' then mas3=0;
if qii3x= 'azt' then mas3=0;
if qii3x= 'd4t' then mas3=0;
if qii3x= 'epivir' then mas3=0;
totmas=mas 1+mas2+mas3;
ifmasl NE 0 and mas2 NE 0 and mas3 NE 0 then totmas= totmas/3;
ifmasl NE 0 and mas2= 0 and mas3 NE 0 then totmas= totmas/2;
ifmasl=O and mas2 NE 0 and mas3 NE 0 then totmas= totmas/2;
ifmasl NE 0 and mas2 NE 0 and mas3=0 then totmas= totmas/2;
if mas 1 NE 0 and mas2=0 and mas3=0 then totmas=totmas;
if mas 1=O and mas2 NE 0 and mas3=0 then totmas=totmas;
if mas 1=O and mas2=0 and mas3 NE 0 then totmas=totmas;
if totmas LT 6 then delete;
totmas 1= 12-totmas;
if totmas 1 = 6 then totmas 1=1;
else if totmas 1 LT 6 then totmas 1 = O;
/*PROGRAM TO CATEGORIZE INDEPENDENT VARIABLES*/
if qi4=1 then qi4=1;
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0;
if qi5=0 then qi5=.;
if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=1;
if qi29=5 then qi29=2;
if qi29=6 then qi29=3;
if qi29=0 then qi29=.;
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if qi3 l =0 then qi3 l =.;
else if qi31 = 1 or qi3 l =2 then qi3 l =O;
else if qi31 = 3 or qi3 l =4 then qi3 l =1;
if qvi52= 0 or qvi52=1 then qvi52=1;
else if qvi52= 2 or qvi52=3 then qvi52=0;
if qi 1 GE 24 and qi 1 Lt 35 then qi 1=1;
else if qil GE 35 and qil LE 41 then qil=2;
elseifqil GT41 thenqi1=3;
if qi5 LT 12 then qi5=0;
else if qi5 GE 12 then qi5=1;
if qil9=0 then qil9=.;
if qi 19=1 then qi 19=1;
if qil9=2 then qil9=0;
if qi 19=3 then qi 19=0;
if qil9=4 then qi19=0;
if qi19=5 then qil9=0;
if qi2=0 then qi2=.;
sex=.;
if qi2='f then sex=O;
if qi2='m' then sex=l;
if qi7=1 then qi7=1;
else if qi7=2 then qi7=0;
if qil8a=l then qil8a=O;
if qi l 8a=2 then qi l 8a=l;
Mqil=.;
ifqil=2 thenMqil=l;
else if qi 1=1 or qi 1=3 then Mqi 1=O;
Hqil=.;
if qil=3 then Hqil=l;
else if qi 1=2 or qi 1=l then Hqi 1=O;
Mqi29=.;
if qi29=2 then Mqi29=1;
else if qi29=1 or qi29=3 then Mqi29=0;
Hqi29=.;
if qi29=3 then Hqi29=1;
else if qi29=1 or qi29=2 then Hqi29=0;
/*PROGRAM TO MEASURE HRQoL*I
if qi3=1 then qi3=5.0;
if qi3=2 then qi3=4.4;
if qi3=3 then qi3=3.4;
if qi3=4 then qi3=2.0;
if qi3=5 then qi3=1.0;
if qi24=1 then qi24=6.0;
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if qi24=2 then qi24=5.4;
if qi24=3 then qi24=4.2;
if qi24=4 then qi24=3.1;
if qi24=5 then qi24=2.2;
if qi24=6 then qi24=1.0;
if qi25=0 then qi25=.;
if qi25=1 and qi24=99 then qi25=6.0;
if qi25=2 and qi24=99 then qi25=4. 75;
if qi25=3 and qi24=99 then qi25=3.5;
if qi25=4 and qi24=99 then qi25=2.25;
if qi25=5 and qi24=99 then qi25=1.0;
if qi25=1 and qi24=1 then qi25=6.0;
if qi25=1 and qi24 GE 2 and qi24 LE 6 then qi25=5;
if qi25=2 and qi24 GE 1 and qi24 LE 6 then qi25=4;
if qi25=3 and qi24 GE 1 and qi24 LE 6 then qi25=3;
if qi25=4 and qi24 GE 1 and qi24 LE 6 then qi25=2;
if qi25=5 and qi24 GE 1 and qi24 LE 6 then qi25=1;
if qi26=0 then qi26=6;
if qi26=1 then qi26=5;
if qi26=2 then qi26=4;
if qi26 GE 3 and qi26 LE 5 then qi26=3;
if qi26 GE 6 and qi26 LE 7 then qi26=2;
if qi26 GE 7 and qi26 LE 28 then qi26=1;
if qi26=99 then qi26=.;
if qi28a=O then qi28a=99;
if qi28b=O then qi28b=99;
if qi28c=O then qi28c=99;
if qi28d=O then qi28d=99;
if qi28e=O then qi28e=99;
if qi28f=O then qi28f=99;
if qi28g=O then qi28g=99;
if qi28h=O then qi28h=99;
if qi28i=O then qi28i=99;
if qi28g=l then qi28g=6;
if qi28g=2 then qi28g=5;
if qi28g=3 then qi28g=4;
if qi28g=4 then qi28g=3;
if qi28g=5 then qi28g=2;
if qi28g=6 then qi28g=l;
if qi28i=l then qi28i=6;
if qi28i=2 then qi28i=5;
if qi28i=3 then qi28i=4;
if qi28i=4 then qi28i=3;
if qi28i=5 then qi28i=2;
if qi28i=6 then qi28i=l;
if qi28b=l then qi28b=6;
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if qi28b=2 then qi28b=S;
if qi28b=3 then qi28b=4;
if qi28b=4 then qi28b=3;
if qi28b=S then qi28b=2;
if qi28b=6 then qi28b=l;
if qi28c=l then qi28c=6;
if qi28c=2 then qi28c=S;
if qi28c=3 then qi28c=4;
if qi28c=4 then qi28c=3;
if qi28c=S then qi28c=2;
if qi28c=6 then qi28c=l;
if qi28f=l then qi28f=6;
if qi28f=2 then qi28f=S;
if qi28f=3 then qi28f=4;
if qi28f=4 then qi28f=3;
if qi28f=S then qi28f=2;
if qi28f=6 then qi28f=l;
GHr=qi3;
BPr=qi24+qi25;
RPr=qi26;
Vrl =qi28a+qi28e+qi28g+qi28i;
if Vrl GE 117 then Vrl =O;
MHrl =qi28b+qi28c+qi28d+qi28f+qi28h;
ifMHrl GE 123 then MHrl=O;

data rakesh3;
set rakesh2;
if qi28a=99 then qi28a=(qi28e+qi28g+qi28i)/3;
if qi28b=99 then qi28b=(qi28c+qi28d+qi28f+qi28h)/4;
if qi28c=99 then qi28c=(qi28b+qi28d+qi28f+qi28h)/4;;
if qi28d=99 then qi28d=(qi28b+qi28c+qi28f+qi28h)/4;
if qi28e=99 then qi28e=(qi28a+qi28g+qi28i)/3;
if qi28f=99 then qi28f=(qi28b+qi28c+qi28d+qi28h)/4;
if qi28g=99 then qi28g=(qi28a+qi28e+qi28i/3);
if qi28h=99 then qi28h=(qi28b+qi28c+qi28d+qi28f)/4;
if qi28i=99 then qi28i=(qi28a+qi28e+qi28g/3);
Vr=qi28a+qi28e+q i28 g+qi28i;
ifVrl=O then Vr=.;
MHr=qi28b+qi28c+qi28d+qi28f+qi28h;
ifMHrl=O thenMHr=.;

GH=(GHr-1)/4*100;
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BP=(BPr-2)/1O*l00;
RP=(RPr-1)/5*100;
V=(Vr-4)/20*100;
MH=(MHr-5)/25*100;
ifGH LE 25 then GH=O;
else if GH GT 25 then GH=l;
if BP LT 42 then BP=O;
else if BP GE 42 then BP=l;
ifV LE 20 then V=O;
else ifV GT 20 then V=l ;
ifMH LT 36 then MH=O;
else ifMH GE 36 then MH=l;
keep Mqil Hqil sex qi4 qi5 qi7 qi18a qi19 Mqi29 Hqi29 qi31 qvi52 GH BP V MH
totmasl ;
/*proc freq;
proc univariate normal plot;
proc freq;
tables MH*qil /all;
tables MH*sex/all;
tables MH*qi4/all;
tables MH*qi5/all ;
tables MH*qi7/all;
tables MH*qi18a/a11;
tables MH*qil9/al1;
tables MH*qi29/all;
tables MH*qi31 /a11;* /
proc logistic descending;
model totmasl = MH Mqil Hqil qi4 qi5 qi19 qi31 /ctable pprob=(O to l by .1 ) lackfit
risklimits;
run;
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